DrTarget Portfolio 2025: Advancing AI-Powered Drug Discovery DrTarget Portfolio 2025: AI-Powered Virtual Screening

Expanding Virtual Screening Capabilities

DrTarget’s 2025 portfolio integrates over 500 new AI-powered virtual screening programs, leveraging data from 800+ PubChem bioassays. These programs enable the exploration of 2 million molecules across a diverse range of therapeutic areas, accelerating early-stage drug discovery.

Harnessing PubChem Data for Smarter Discovery

By integrating vast datasets from PubChem & ChEMBL, DrTarget refines hit identification strategies, ensuring high-confidence predictions for experimental validation. Our approach facilitates:

🔹 AI-enhanced lead optimization
🔹 Chemical property assessment for drug-likeness
🔹 Advanced computational workflows for novel targets

802 Pubchem assays support 576 machine learning projects associated to 249 diseases corresponding to 29 therapeutic areas. The assays involve > 400 different phenotypes and 461 genes.

See PubChem assays supporting machine learning programs clicking in the therapeutic area tabs.

OTHER NON PROLIFERATIVE DISEASES

Other non-proliferative diseases treeMap with PubChem assays supporting machine learning on them. Click to expand treemaps.

Find drTarget portfolio details in table. Use scroll bar or search funtion to select specific therapeutic areas, molecular targets or phenotypes.

area	disease	program	assayType	PubChemAssay	gene	testedComopunds	activeCompounds
antiBacterial	plague	Yersinia pestis	targetBased	YopH HTS	YopH	139929	223
psychiatricDisorder	schizophrenia	Wnt/Beta-catenin pathway	phenotypic	Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity		304218	3630
biologicalProcess	geneRegulation	start codon recognition	phenotypic	Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity		347159	450
gastroIntestinal	intestinal disease	RORC	targetBased	VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity	RORC	304060	10600
nervousSystem	neurodegeneration	Caspase6Inhibitors	targetBased	VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2	CASP6	344318	1854
nervousSystem	neurodegeneration	USP30	targetBased	USP30 deubiquitinase inhibition: Primary qHTS	USP30	47480	2500
nervousSystem	neurodegeneration	USP28	targetBased	USP28 deubiquitinase inhibition: Primary qHTS	USP28	47480	1413
immune	immunodeficiency disease	USP17L5	targetBased	USP17 deubiquitinase inhibition: Primary qHTS	USP17L5	47480	3075
		USP10	targetBased	USP10 deubiquitinase inhibition: Primary qHTS	USP10	47480	509
cancer	neoplastic disease or syndrome	USP8	targetBased	USP8 deubiquitinase inhibition: Primary qHTS	USP8	47480	2010
immune	fibrosis	p47phoxInhibitors	targetBased	uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)	NCF1	217454	1142
nervousSystem	neurodegeneration	MCL1	targetBased	uHTS of Mcl-1/Noxa interaction inhibitors	MCL1	217330	3334
nervousSystem	neurodegeneration	MCL1	targetBased	uHTS of Mcl-1/Bid interaction inhibitors	MCL1	218602	2129
		SENP7	targetBased	uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7)	SENP7	331670	4902
nervousSystem	neurodegeneration	SENP6	targetBased	uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6)	SENP6	330392	5817
muculoEskeletalConnective	connective tissue disease	NLRP3	targetBased	uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	330392	1295
biologicalProcess	alcalinePhosphatase	ALPI_inhibitors	targetBased	uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase	ALPI	331670	664
biologicalProcess	alcalinePhosphatase	ALPI_inhibitors	targetBased	uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase	ALPI	330392	393
metabolicEndocrine	cholesterolLevels	ALPI_activators	targetBased	uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase	ALPI	331670	785
metabolicEndocrine	cholesterolLevels	ALPI_activators	targetBased	uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase	ALPI	330392	537
immune	Crohn's disease	NOD2	targetBased	uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	292323	1836
		NOD1	targetBased	uHTS luminescence assay for the identification of compounds that inhibit NOD1	NOD1	289422	2997
immune	immunomodulation	NFKB1_activation	phenotypic	uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation		330392	1733
immune	immunomodulation	NFKB1_activation	phenotypic	uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation		331670	1077
		UBE2N	targetBased	uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay	UBE2N	330393	1538
muculoEskeletalConnective	boneDisease	ALPL_inhibitors	targetBased	uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL	195560	517
cancer	resistanecToRadiation	SUMO1	targetBased	uHTS identification of SUMO1-mediated protein-protein interactions	SUMO1	363840	1202
metabolicEndocrine	type I and type II diabetes	beta-cell replication	phenotypic	uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line		330392	956
metabolicEndocrine	obesity, diabetes and hyperlipidemia	TriglycerideAccumulationInhibitors	phenotypic	uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay		226721	1501
metabolicEndocrine	obesity, diabetes and hyperlipidemia	Rev-erb Alpha	phenotypic	uHTS identification of small molecule modulators of Rev-erb Alpha.		371540	2956
nervousSystem	neurodegeneration	GRIN3A	targetBased	uHTS identification of small molecule modulators of NR3A	GRIN3A	339772	8480
cardioVascular	myocardial infarction	myocardial damage	phenotypic	uHTS identification of small molecule modulators of myocardial damage		359244	2272
cancer	glioblastoma	inhibitors of TWEAK-Fn14 interactions	phenotypic	uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay		362063	7302
		TIM23	targetBased	uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay	TIM23	331671	4405
		TIM10	targetBased	uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay	TIM10	331671	7319
		TIM10	targetBased	uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay	TIM10	331671	4615
nervousSystem	neurodegeneration	mPTP	phenotypic	uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay		363840	5033
nervousSystem	neurodegeneration	SENP1	targetBased	uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay	SENP1	363840	774
nervousSystem	neurodegeneration	PTPN5	targetBased	uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay	PTPN5	359244	887
antiMicrobial	malaria	Plasmodium berghei	targetBased	uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay	G6PD-6PGL	348923	2710
metabolicEndocrine	obesity associated insulin resistance and the metabolic syndrome	ACP1_inhibitors	targetBased	uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay	ACP1	363840	817
biologicalProcess	Ubiquitination	COPS5	targetBased	uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay	COPS5	363840	1401
cancer	acuteLymphoblasticLymphoma	artemis_inhibitors	targetBased	uHTS identification of small molecule inhibitors of Artemis endonuclease activity via a fluorescence intensity assay	DCLRE1C	30104	235
cancer	cancerGeneral	FASN_inhibitors	targetBased	uHTS identification of small molecule inhibitors of the thioesterase domain of fatty acid synthase via a fluorescence intensity assay	FASN	362063	2427
cancer	neoplastic disease or syndrome	OPRK1	targetBased	uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	290355	265
		GPR183	targetBased	uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay	GPR183	363840	2946
cancer	metastasis	CCR6_antagonists	targetBased	uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay	CCR6	340696	1654
cancer	cancerGeneral	APLNR_antagonists	targetBased	uHTS identification of small molecule antagonists of the APJ receptor via a luminescent beta-arrestin assay	APLNR	330392	1062
cardioVascular	hypertension	APLNR_agonists	targetBased	uHTS identification of small molecule agonists of the APJ receptor via a luminescent beta-arrestin assay	APLNR	330348	347
cancer	cancerGeneral	PERK-elF2a-CHOP pathway activators	phenotypic	uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay		331671	1124
cytoprotection	cellRecovery	IRE1-XBP1 pathway activators	phenotypic	uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay		331671	1099
		LARGE	targetBased	uHTS identification of small molecule activators of alpha dystroglycan glycosylation	LARGE	363840	805
		SKN-1	targetBased	uHTS identification of SKN-1 Inhibitors in a fluoresence assay	SKN-1	363840	1794
		NRP1	targetBased	uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay	NRP1	363840	3086
cancer	neoplastic disease or syndrome	PABPC1	targetBased	uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay	PABPC1	359244	1307
antiBacterial	E. coli	Escherichia coli (strain K12)	targetBased	uHTS identification of MazEF TA System activators via a fluorescence-based single-stranded RNase assay	MAZF	348923	1104
		RPN11	targetBased	uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay	RPN11	359244	2134
antiBacterial	S. aureus	NadD_inhibitors	targetBased	uHTS identification of inhibitors of NadD in a Colorimetric assay	NaMNAT	362063	2815
muculoEskeletalConnective	bone disease	MMP14	targetBased	uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay	MMP14	361500	222
cancer	neoplastic disease or syndrome	UBE2M	targetBased	uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay	UBE2M	363840	2123
cancer	cancerGeneral	HIF-2a_inhibitors	targetBased	uHTS identification of HIF-2a Inhibitors in a luminesence assay	EPAS1	363840	2624
muculoEskeletalConnective	non-syndromic polydactyly	GLI1	targetBased	uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay	GLI1	338328	2501
cancer	cancerGeneral	DNMT1	targetBased	uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	359244	2975
antiBacterial	Clostridium kluyveri	DiaphoraseInhibitors	targetBased	uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays	DLD	194152	1342
rareDiseases	cysticFibrosis	NFKB1	pathwayBased	uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	359244	3094
cancer	metastasis	CXCR6_inhibitors	targetBased	uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay	CXCR6	362063	1298
cancer	neoplastic disease or syndrome	RUNX1	targetBased	uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	218234	1620
cancer	neoplastic disease or syndrome	RUNX1	targetBased	uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	215667	993
cancer	neoplastic disease or syndrome	TNFRSF10B	targetBased	uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay	TNFRSF10B	363840	3764
antiViral	HIV	APOBEC3G_inhibitors	targetBased	uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay	APOBEC3G	331753	931
antiViral	HIV	APOBEC3A_inhibitors	targetBased	uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay	APOBEC3A	331753	1372
nervousSystem	drugAddiction	CRHBP_antagonists	targetBased	uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex	CRHBP	348923	2056
biologicalProcess	toolCompounds	CRHBP_agonists	targetBased	uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex	CRHBP	348923	1622
respiratory	respiratory system disease	UBE2I	targetBased	uHTS HTRF assay for identification of inhibitors of SUMOylation	UBE2I	290915	1039
		TNFSF10	targetBased	uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells	TNFSF10	217035	883
biologicalProcess	autophagy	EIF4E_inhibition	targetBased	uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation	EIF4E	217332	799
antiViral	EBV	Epstein-Barr virus	targetBased	uHTS for Small Molecule Inhibitiors of Epstein-Barr Virus Inhibitors	Q1HVG2	218602	926
cancer	neoplastic disease or syndrome	MDM4	targetBased	uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.	MDM4	331671	10022
nervousSystem	neurodegeneration	calpainInhibitors	targetBased	uHTS for Calpain Inhibitors	CAPN2	218602	799
		YWHAZ	targetBased	uHTS for 14-3-3/Bad interaction inhibitors	YWHAZ	217332	1549
cancer	neoplastic disease or syndrome	SENP8	targetBased	uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8)	SENP8	363840	2341
		HKDC1	targetBased	uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing I (HKDC1)	HKDC1	340696	540
biologicalProcess	autophagy	ATG4B_inhibitors	pathwayBased	uHTS fluorescent assay for identification of inhibitors of ATG4B	ATG4B	340119	1734
nervousSystem	neurodegeneration	APAF1_inhibitors	targetBased	uHTS Fluorescent assay for identification of inhibitors of Apaf-1	APAF1	331671	2353
cancer	cancerGeneral	APAF1_activators	targetBased	uHTS Fluorescent assay for identification of activators of Apaf-1	APAF1	331671	1041
cancer	neoplastic disease or syndrome	PABPC1	targetBased	uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP)	PABPC1	290915	2982
cancer	cancerGeneral	EIF4H	targetBased	uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (eIF4H)	EIF4H	290915	2744
antiViral	HIV	HIV type 1	targetBased	uHTS fluorescence assay for the identification of Human Immunodeficiency Virus Fusion Inhibitors.	ENV	292323	890
biologicalProcess	nervousSystemDevelopment	CTDSP1_inhibitors	targetBased	uHTS Colorimetric assay for identification of inhibitors of Scp-1	CTDSP1	340696	2986
cancer	cancerGeneral	VHR1_inhibitors	targetBased	uHTS absorbance assay for the identification of compounds that inhibit VHR1.	DUSP3	291006	1524
reproductiveSystem	sex hormone-binding globulin measurement	PHOSPHO1	targetBased	uHTS absorbance assay for the identification of compounds that inhibit PHOSPHO1	PHOSPHO1	288321	3164
prionDisease	prionDisease	PRNP	targetBased	TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	369953	1596
metabolicEndocrine	obesity	MC4R	targetBased	TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	356160	1703
antiViral	HIV	HIV type 1	targetBased	TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9	ENV	362577	1546
cancer	leukemia	ABL1_interaction	targetBased	TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1	359207	1432
antiViral	HIV	PSIP1	targetBased	TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration	PSIP1	369953	2353
cancer	Reactivate the silenced genes in cancer cells	MBD2	targetBased	TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide	MBD2	369953	1149
antiViral	HCV	Hepacivirus hominis	targetBased	TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization	ABC47431	302663	998
nervousSystem	neurodegeneration	NR2E3	targetBased	TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).	NR2E3	314998	380
immune	Immune dysregulation disease with immunodeficiency	IFNG	targetBased	Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	67275	2509
metabolicEndocrine	thyroid disease	THRB	targetBased	Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	276265	806
cardioVascular	antithrombotic	F2_modulation	targetBased	Thrombin 1536 HTS	F2	217233	557
antiBacterial	K. pneumonia	Klebsiella pneumonia SSB-PriA interaction	targetBased	SSB-PriA antibiotic resistant target AlphaScreen	SSB	431236	2568
respiratory	pulmonary function measurement	ID4	targetBased	SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity	ID4	31324	362
respiratory	bronchial disease	IL1RL1	targetBased	Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	75924	1804
antiMicrobial	giardiasis	Giardia lamblia	phenotypic	Small Molecules that selectively kill Giardia lamblia: qHTS		342452	530
cancer	hepatocellularCarcinoma	miR122_activators	phenotypic	Small molecule inhibitors of miR122 Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity		333274	1022
antiViral	HCV	miR122_inhibitors	phenotypic	Small molecule inhibitors of miR122 Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity		333274	472
cancer	neoplastic disease or syndrome	FGF22_inhibitors	targetBased	Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity	FGF22	339650	5128
antiBacterial	antibacterials	TB	phenotypic	several TB strains
biologicalProcess	secretionPath	Modulators of Post-Golgi Transport	phenotypic	Screening for Modulators of Post-Golgi Transport, Control Strain		97518	4851
antiBacterial	S. Pneumoniae	Streptococcus pneumoniae serotype 2 (strain D39 / NCTC 7466)	targetBased	Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - PMK	MVAK2	65392	319
antiBacterial	S. Pneumoniae	Streptococcus Pneumoniae	targetBased	Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - MK	MK	65241	316
antiBacterial	S. Pneumoniae	Streptococcus pneumoniae serotype 2 (strain D39 / NCTC 7466)	targetBased	Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - DPM-DC	MVAD	65385	320
antiBacterial	tuberculosis	Mycobacterium Tuberculosis sensitization to betaLactam	phenotypic	Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics		327901	876
cancer	neoplastic disease or syndrome	SMARCA4	targetBased	Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	344733	7043
cancer	cancerGeneral	RMI FANCM intereaction	phenotypic	Screen for inhibitors of RMI FANCM (MM2) intereaction		69794	402
biologicalProcess	toolCompounds	lifespan	phenotypic	Screen for Chemicals that Shorten Yeast Lifespan		138737	710
cancer	cancerGeneral	RAM network inhibitors	phenotypic	Screen for Chemicals that Inhibit the RAM Network		194550	3545
biologicalProcess	senescence	lifespan	phenotypic	Screen for Chemicals that Extend Yeast Lifespan		132777	904
muculoEskeletalConnective	osteoporosis	Schnurri-3 Inhibitors	targetBased	Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2	HIVEP3	356883	1841
nervousSystem	neurodegeneration	S100A4	targetBased	S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity	S100A4	352235	501
antiFungal	candidiasis	Candida albicans (strain SC5314 / ATCC MYA-2876) (Yeast)	targetBased	Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity	RTT109	328088	521
cancer	neoplastic disease or syndrome	RBX1	targetBased	ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	143816	859
muculoEskeletalConnective	bone disease	GRK2	targetBased	RNA aptamer-based HTS for inhibitors of GRK2	GRK2	327939	1924
antiBacterial	tuberculosis	RmlC_inhibitors	phenotypic	Rml C and D inhibition 384-well mixture HTS		106271	417
biologicalProcess	EpigeneticControl	EpigeneticControl	phenotypic	Quantitative High-Throughput Screen for Regulators of Epigenetic Control		272097	537
industrial	lipidBiosynthesis	fuelBiosynthesis	phenotypic	qHTS screening for TAG (triacylglycerol) accumulators in algae		43680	367
cancer	cancerGeneral	ATAD5_inhibitors	targetBased	qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1	ATAD5	330107	7652
cancer	cancerGeneral	ATAD5_inhibitors	targetBased	qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1	ATAD5	330109	4174
cancer	nonSmallCellLungCarcinoma	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	TP53	124022	1156
cancer	nonSmallCellLungCarcinoma	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	TP53	125394	1890
cancer	nonSmallCellLungCarcinoma	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	TP53	54513	338
cancer	nonSmallCellLungCarcinoma	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	TP53	54509	528
antiMicrobial	malaria	Plasmodium falciparum	phenotypic	qHTS Primary assay for Inhibitors of Plasmodium falciparum Dd2 growth in vitro		123608	5316
antiViral	SARS-CoV	SARS-CoV	targetBased	qHTS of Yeast-based Assay for SARS-CoV PLP	REP	328641	609
antiMicrobial	trypanosomiasis	T. brucei	phenotypic	qHTS of Trypanosoma Brucei Inhibitors	TB08.30K1.730	406726	491
nervousSystem	inherited neurodegenerative disorder	TARDBP	pathwayBased	qHTS of TDP-43 Inhibitors: NCGC Sytravon Library Screen	TARDBP	45163	203
nervousSystem	neurodegeneration	TARDBP	pathwayBased	qHTS of TDP-43 Inhibitors	TARDBP	403703	7150
immune	COPD	Nrf2 activators	pathwayBased	qHTS of Nrf2 Activators	NFE2L2	403871	1243
cancer	neoplasm of thorax	IL2	targetBased	qHTS of IL-2 Activators	IL2	364617	238
metabolicEndocrine	T2Diabetes	GLP1R PAMs	targetBased	qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R	405130	6428
metabolicEndocrine	endocrine pancreas disorder	GLP1R	targetBased	qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	405130	6428
metabolicEndocrine	T2Diabetes	GLP1R agonists	targetBased	qHTS of GLP-1 Receptor Agonists	GLP1R	373462	23
nervousSystem	neurodegeneration	D3_PAMs	targetBased	qHTS of D3 Dopamine Receptor Potentiators: qHTS	DRD3	407539	2380
nervousSystem	drugAddiction	D3_antagonists	targetBased	qHTS of D3 Dopamine Receptor Antagonist: qHTS	DRD3	364051	9106
nervousSystem	neurodegeneration	D3_agonists	targetBased	qHTS of D3 Dopamine Receptor Agonist: qHTS	DRD3	407539	2380
nervousSystem	inherited neurodegenerative disorder	SNCA	pathwayBased	qHTS of alpha-syn Inhibitors	SNCA	368791	501
nervousSystem	Huntington disease	HTT	targetBased	qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP)	HTT	223611	305
nervousSystem	Huntington disease	HTT	targetBased	qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP)	HTT	220571	2380
antiBacterial	E. coli	Escherichia coli (strain K12)	targetBased	qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent)	AMPC	330677	1730
nervousSystem	sporadic amyotrophic lateral sclerosis	FUS_asupressors	targetBased	qHTS for Suppressors of FUS Proteinopathy: Primary screen using FUS-linked yeast assay	FUS	385746	932
antiViral	VACV	Vaccinia virus (VACV)	phenotypic	qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS	3707576	326363	1520
antiViral	VACV	Vaccinia virus (VACV)	phenotypic	qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS	3707576	306737	1931
psychiatricDisorder	anxiety	TRHR	targetBased	qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers	TRHR	361330	2424
metabolicEndocrine	thyroid disease	TRHR	targetBased	qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.	TRHR	361330	651
nervousSystem	neurodegeneration	PI4K2A	targetBased	qHTS for small molecular inhibitors of PI4K2A	PI4K2A	414643	532
muculoEskeletalConnective	bone development disease	PTH1R	targetBased	qHTS for PTHR1 Agonists: Primary Screen	PTH1R	405685	308
cancer	neoplastic disease or syndrome	WRN	targetBased	qHTS for Inhibitors of WRN Helicase	WRN	364011	1678
antiViral	HIV	APOBEC3G_inhibitors	targetBased	qHTS for Inhibitors of Vif-A3G Interactions: qHTS	APOBEC3G	402348	311
antiViral	HIV	APOBEC3F_inhibitors	targetBased	qHTS for Inhibitors of Vif-A3F Interactions: qHTS	APOBEC3F	383848	765
immune	fibrosis	TGFB1	pathwayBased	qHTS for Inhibitors of TGF-b	TGFB1	403345	4970
nervousSystem	neurodegeneration	MAPT	pathwayBased	qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	267412	5703
nervousSystem	inherited neurodegenerative disorder	MAPT	pathwayBased	qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	271402	1048
immune	autoimmuneDisorders	RORCgammaPathwayInhibitors	pathwayBased	qHTS for inhibitors of ROR gamma transcriptional activity	RORC	305439	16717
cancer	neoplastic disease or syndrome	POLK	targetBased	qHTS for Inhibitors of Polymerase Kappa	POLK	395295	2034
respiratory	lower respiratory tract disease	POLI	targetBased	qHTS for Inhibitors of Polymerase Iota	POLI	386063	3989
geneticDisorder	Rare genetic skin disease	POLH	targetBased	qHTS for Inhibitors of Polymerase Eta	POLH	388717	4730
immune	type II hypersensitivity reaction disease	PLK1	targetBased	qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen	PLK1	364065	10181
nervousSystem	neurodegeneration	PIP4K2A	targetBased	qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K)	PIP4K2A	328860	4078
		HEL-S-26	targetBased	qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS	HEL-S-26	387604	365
cardioVascular	Rare genetic cardiac disease	KCNH2	targetBased	qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	343666	1267
psychiatricDisorder	schizophrenia	KCNH2	targetBased	qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	342084	3260
immune	Inflammation CASP COPD	IL-1b Inflammasome	pathwayBased	qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL1B	362051	17187
nervousSystem	inherited neurodegenerative disorder	TDP1	targetBased	qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT	TDP1	416856	49238
nervousSystem	inherited neurodegenerative disorder	TDP1	targetBased	qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT	TDP1	416824	63248
geneticDisorder	autosomal recessive disease	GLS	targetBased	qHTS for Inhibitors of Glutaminase (GLS)	GLS	405291	844
hematologic	inherited bleeding disorder, platelet-type	PLAU	targetBased	qHTS for Inhibitors of Cell Surface uPA Generation	PLAU	325247	1021
antiViral	Margburg virus	Margburg virus entry	phenotypic	qHTS for inhibitors of binding or entry into cells for Marburg Virus		284160	4700
antiViral	LassaVirus	Lassa virus entry	phenotypic	qHTS for Inhibitors of binding or entry into cells for Lassa Virus		297156	3648
antiMicrobial	malaria	Plasmodium falciparum	targetBased	qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen	AMA1-RON	364096	735
cancer	glioma	gliomaWithIdh1Mutations	targetBased	qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line	HEL-S-26	364464	5966
cancer	glioma	gliomaWithIdh1Mutations	phenotypic	qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line		364464	7438
nervousSystem	neurodegeneration	APP_inhibitors	targetBased	qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP	404343	257
rareDiseases	McCune-Albright syndrome (MAS)	GNAS	targetBased	qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	337446	1356
metabolicEndocrine	thyroid disease	RAPGEF3	targetBased	qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen	RAPGEF3	364614	517
psychiatricDisorder	mental process	RAPGEF4	targetBased	qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen	RAPGEF4	364614	663
geneticDisorder	developmental defect during embryogenesis	MCOLN1	targetBased	qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1)	MCOLN1	400814	482
cancer	neoplastic disease or syndrome	GPR32	targetBased	qHTS for Agonists of Human Resolvin D1 Receptor DRV1	GPR32	47473	1217
metabolicEndocrine	hereditary hypoparathyroidism	GNAS	targetBased	qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	334825	423
psychiatricDisorder	mental process	RAPGEF4	targetBased	qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen	RAPGEF4	364614	290
metabolicEndocrine	thyroid disease	RAPGEF3	targetBased	qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen	RAPGEF3	364614	268
rareDiseases	muscularDistrophy	CGA_integrin_activators	targetBased	qHTS for Activators of Integrin-Mediated Alleviation for Muscular Dystrophy	CGA	345855	222
immune	autoimmuneDisorders	RORCgammaPathwayInhibitors	pathwayBased	qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway	RORC	7671	874
metabolicEndocrine	insulinSensitization	RXRA_pathway_agonists	pathwayBased	qHTS assay to identify small molecule agonists of the RXR signaling pathway:	RXR	7671	173
cancer	breastCancer	BRCA1 activation	pathwayBased	qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1	376029	3978
antiMicrobial	trypanosomiasis	Trypanosoma brucei brucei (strain 927/4 GUTat10.1)	targetBased	qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase	TB03.3K10.320	330677	557
antiMicrobial	schistosomiasis	Schistosoma mansoni (Blood fluke)	targetBased	qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins	TGR	356643	10735
cancer	neoplastic disease or syndrome	L3MBTL1	targetBased	qHTS Assay for the Inhibitors of L3MBTL1	L3MBTL1	225309	1492
nervousSystem	neurodegeneration	FEN1_inhibitors	targetBased	qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).	FEN1	386270	1331
nervousSystem	inherited neurodegenerative disorder	MAPT	targetBased	qHTS Assay for Tau Filament Binding	MAPT	69668	1391
biologicalProcess	mitochondrialFusion	mitochondrialFusion	phenotypic	qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion		322166	738
immune	COPD	Antioxidant Response Element	phenotypic	qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway		7671	943
cancer	cancerGeneral	TP53	pathwayBased	qHTS assay for re-activators of p53 using a Luc reporter	TP53	321427	201
rareDiseases	Niemann Pick Type C (NPC)	RAB9A	pathwayBased	qHTS Assay for Rab9 Promoter Activators	RAB9A	320603	9133
antiMicrobial	trypanosomiasis	Trypanosoma cruzi	targetBased	qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent)	P25779	195013	4500
antiMicrobial	trypanosomiasis	Trypanosoma cruzi	targetBased	qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent)	P25779	195013	848
rareDiseases	Niemann Pick Type C (NPC)	NPC1	pathwayBased	qHTS Assay for NPC1 Promoter Activators	NPC1	320682	7575
cancer	cancerGeneral	miRNA_modulators	phenotypic	qHTS Assay for Modulators of miRNAs and/or Inhibitors of miR-21		333510	3282
cancer	cancerGeneral	MDR1-selective compounds	targetBased	qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	ABCB1	395981	5516
cancer	cancerGeneral	MDR1-selective compounds	targetBased	qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	ABCB1	396029	13426
metabolicEndocrine	obesity	lipidStorageInhibitors	phenotypic	qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells		320858	2061
cancer	leukemia	Menin-MLL_inhibitors	targetBased	qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	MEN1	263421	615
nervousSystem	inherited neurodegenerative disorder	TDP1	targetBased	qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1)	TDP1	344442	978
nervousSystem	inherited auditory system disease	SIX1	targetBased	qHTS Assay for Inhibitors of the Six1/Eya2 Interaction	SIX1	364053	2026
antiViral	HCMV	HCMV inhibitors	phenotypic	qHTS Assay for inhibitors of the human cytomegalovirus (HCMV)		403256	18370
cancer	cancerGeneral	APEX1_inhibitors	targetBased	qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1)	APEX1	345898	1172
antiViral	HIV	HIV-VPR	targetBased	qHTS Assay for Inhibitors of the HIV-1 protein Vpr	VPR	361879	750
cancer	neoplastic disease or syndrome	MAPK1	pathwayBased	qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	131324	544
cancer	neoplastic disease or syndrome	MAPK1	pathwayBased	qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	70898	707
geneticDisorder	developmental defect during embryogenesis	RBBP8	targetBased	qHTS Assay for Inhibitors of the CtBP/E1A Interaction	RBBP8	335214	1652
nervousSystem	Neurodevelopmental disorder	GNAI1	targetBased	qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore)	GNAI1	229888	1007
cancer	neoplastic disease or syndrome	RECQL	targetBased	qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1)	RECQL	234915	1245
		SNUPN	targetBased	qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation	SNUPN	340719	242
cancer	neoplastic disease or syndrome	TXNRD1	targetBased	qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS	TXNRD1	386663	3977
antiMicrobial	leishmaniasis	Leishmania mexicana	targetBased	qHTS Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase (LmPK)	PYK	292732	1088
biologicalProcess	epigenetics	KDM4A	targetBased	qHTS Assay for Inhibitors of JMJD2A-Tudor Domain	KDM4A	384527	16920
antiViral	H1N1	Influenza NS1	targetBased	qHTS Assay for Inhibitors of Influenza NS1 Protein Function	NS1	269561	1073
cancer	cancerGeneral	lactateDehydrogenaseInhibitors	targetBased	qHTS assay for inhibitors of human lactate dehydrogenase	LDHA	476056	732
geneticDisorder	developmental defect during embryogenesis	HSD17B10	targetBased	qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4	HSD17B10	73912	5649
muculoEskeletalConnective	hypertrophic osteoarthropathy, primary, autosomal recessive, 1	HPGD	targetBased	qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase)	HPGD	148480	6428
cancer	cancerGeneral	EHMT2_inhibitors	targetBased	qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a	EHMT2	348338	30875
antiViral	HCV	HCV inhibitors	phenotypic	qHTS Assay for Inhibitors of Hepatitis C Virus (HCV)		339573	11624
geneticDisorder	developmental defect during embryogenesis	HSD17B10	targetBased	qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)	HSD17B10	72072	2464
cancer	neoplastic disease or syndrome	KAT2A	targetBased	qHTS Assay for Inhibitors of GCN5L2	KAT2A	381571	792
antiMicrobial	giardiasis	Giardia intestinalis (strain ATCC 50803 / WB clone C6) (Giardia lamblia)	targetBased	qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia	FBA	287738	2034
nervousSystem	neurodegeneration	POLB	targetBased	qHTS Assay for Inhibitors of DNA Polymerase Beta	POLB	334457	4509
cancer	cancerGeneral	BLM_inhibitors	targetBased	qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM	347933	673
nervousSystem	neurodevelopmentalDisorders	BAZ2B_modulators	targetBased	qHTS Assay for Inhibitors of BAZ2B	BAZ2B	356826	15709
antiBacterial	B. subtilis	Bacillus subtilis	targetBased	qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase)	FFP	306599	10840
metabolicEndocrine	obesity	ALDH1A1_inhibitors	targetBased	qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1)	ALDH1A1	216881	16026
cancer	cancerGeneral	ALOX15B_inhibitors	targetBased	qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2)	ALOX15B	107252	595
immune	immunomodulation	ALOX15_inhibitors	targetBased	qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase)	ALOX15	73174	1034
cancer	neoplastic disease or syndrome	KDM4E	targetBased	qHTS Assay for Inhibitors of Human Jumonji Domain Containing 2E (JMJD2E)	KDM4E	226914	3523
		GBA	targetBased	qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease	GBA	321552	295
muculoEskeletalConnective	familial cardiomyopathy	GAA_inhibitors	targetBased	qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA	302297	1165
psychiatricDisorder	mental or behavioural disorder	IMPA1	targetBased	qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	205582	727
nervousSystem	ataxiaTelangiectasia	ATM_modulators	targetBased	qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM	322361	619
visualSystem	eye disease	FTL	targetBased	qHTS Assay for Identification of Novel General Anesthetics	FTL	341499	255
antiViral	FMDV	Foot-and-mouth disease virus	phenotypic	qHTS Assay for Foot and Mouth Disease Virus Antivirals: Primary Screen against the MLPCN compound library	AAA42670	404063	1959
rareDiseases	SMA	SMN1; SMN2	pathwayBased	qHTS Assay for Enhancers of SMN2 Splice Variant Expression	SMN1; SMN2	208489	5817
cancer	cancerGeneral	Disrupters of an Hsp90 Co-Chaperone Interaction	phenotypic	qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction		69668	300
antiBacterial	anthrax	Bacillus anthracis Lethal Toxin Internalization	phenotypic	qHTS Assay for Anthrax Lethal Toxin Internalization		68961	466
immune	fibrosis	relaxin PMs	targetBased	qHTS Assay for Antagonists of the Relaxin Receptor RXFP1Taking the negative queue for PMs	RXFP1	350177	2058
cancer	cancerGeneral	relaxinInhibitors	targetBased	qHTS Assay for Antagonists of the Relaxin Receptor RXFP1	RXFP1	350177	2058
psychiatricDisorder	anxiety	NPSR1	targetBased	qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction	NPSR1	220862	2309
biologicalProcess	apoptosisInhibition	caspase1Inhibitors	phenotypic	qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region		73912	779
metabolicEndocrine	thyroid disease	TSHR	targetBased	qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	72026	1794
metabolicEndocrine	thyroid disease	TSHR	targetBased	qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	72026	352
immune	fibrosis	RXFP1	targetBased	qHTS Assay for Agonists of the Relaxin Receptor RXFP1	RXFP1	362198	1084
nervousSystem	neurodegeneration	PKM	targetBased	qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase	PKM	263662	892
muculoEskeletalConnective	familial cardiomyopathy	GAA	targetBased	qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	199169	715
antiBacterial	B. subtilis	Bacillus subtilis (strain 168)	targetBased	qHTS Assay for Activators of ClpP	CLPP	338378	6439
antiViral	SARS-CoV	SARS-CoV	targetBased	QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro)	AAZ82016	290726	405
antiMicrobial	malaria	Plasmodium falciparum (isolate 3D7)	targetBased	QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP).	M18AAP	290726	3497
antiMicrobial	malaria	PFM18AAPinhibitorsCounterscreen	targetBased	QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).	CTSL1	302663	1482
cancer	breastCancer	ADAM17_inhibitors	targetBased	QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.	ADAM17	369953	3080
cancer	breastCancer	ADAM10_inhibitors	targetBased	QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.	ADAM10	369953	2294
cancer	neoplastic disease or syndrome	PLA2G3	targetBased	QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2)	PLA2G3	369953	2089
antiBacterial	Geobacillus stearothermophilus	Geobacillus stearothermophilus (Bacillus stearothermophilus)	targetBased	Pyruvate Kinase	PYK	51415	602
antiBacterial	E. coli	Escherichia coli (strain K12)	targetBased	Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent)	AMPC	69668	1256
immune	rheumatoidArthritis	Inhibitors of CD40 Signaling	phenotypic	Primary Screen Inhibitors of CD40 Signaling in BL2 Cells Measured in Cell-Based System Using Plate Reader - 7124-01_Inhibitor_SinglePoint_HTS_Activity		82418	778
psychiatricDisorder	mental or behavioural disorder	KDM5B	targetBased	Primary screen for KDM5B Histone Demethylases FDH-coupled qHTS	KDM5B	217819	5697
metabolicEndocrine	endocrine pancreas disorder	INS	targetBased	Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	127961	1153
nervousSystem	AD	APP_inhibitors	pathwayBased	Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP	193714	1590
metabolicEndocrine	endocrine pancreas disorder	INS	targetBased	Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	128695	1039
nervousSystem	neurodegeneration	APP_inhibitors	pathwayBased	Primary screen for compounds that activate Alzheimer's amyloid precursor	APP	193400	1987
		NTMT1	targetBased	Primary qHTS for Inhibitors of N-terminal methyltransferase 1 (NTMT1): MTaseGlo Assay	NTMT1	56440	1336
nervousSystem	spinocerebellarAtaxia	ATXN2_repressors	targetBased	Primary qHTS for Inhibitors of ATXN expression	ATXN2	358434	2554
nervousSystem	Huntington disease	HTT	targetBased	Primary qHTS for Identification of Small Molecule Inhibitors of Huntingtin Promoter Activity	HTT	48068	449
antiMicrobial	malaria	Plasmodium falciparum	phenotypic	Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation		323200	22332
antiMicrobial	malaria	Plasmodium falciparum	phenotypic	Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation		304969	18055
nervousSystem	neurodegeneration	IP6K1	targetBased	Primary qHTS assay for small molecule inhibitors of Inositol hexaphosphate kinase 1 (IP6K1)	IP6K1	143229	1157
cancer	cancerGeneral	ALOX12_inhibitors	targetBased	Primary qHTS assay for inhibitors of human arachidonate 12S-lipoxygenase (ALOX12): Round 2	ALOX12	564288	6030
nervousSystem	inherited neurodegenerative disorder	GPT2	targetBased	Primary qHTS assay for inhibitors of Glutamate pyruvate transaminase 2 (GPT2)	GPT2	98912	236
nervousSystem	inherited neurodegenerative disorder	SNCA	pathwayBased	Primary qHTS assay for inhibitors of alpha-synuclein gene (SNCA) expression	SNCA	140118	236
immune	immunomodulation	AICDA_inhibitors	targetBased	Primary qHTS assay for inhibitors of Activation Induced Cytidine Deaminase (AID): AID signal	AICDA	90878	289
antiViral	FMDV	Foot-and-mouth disease virus	targetBased	Primary qHTS Assay for Foot and Mouth Disease Virus Antivirals against NCGC Sytravon and CBC Compound Libraries: Renilla Luciferase Signal	P03308	117258	373
antiViral	FMDV	Foot-and-mouth disease virus	targetBased	Primary qHTS Assay for Foot and Mouth Disease Virus Antivirals against NCGC Sytravon and CBC Compound Libraries: Firefly Luciferase Signal	P03308	117258	273
immune	type II hypersensitivity reaction disease	S1PR3	targetBased	Primary HTS Assay for S1P3 Antagonists	S1PR3	169141	462
immune	immunomodulation	NFkB nuclear translocation	phenotypic	Primary HTS assay for chemical potentiators of IL-1B stimulated NFkB nuclear translocation		94231	282
immune	immunomodulation	VCAM1_expression	targetBased	Primary HTS assay for chemical inhibitors of TNF alpha stimulated VCAM1 expression	VCAM1	94498	457
immune	immunomodulation	E-selectinExpression	targetBased	Primary HTS assay for chemical inhibitors of TNF alpha stimulated E-Selectin expression	SELE	118096	843
psychiatricDisorder	major depressive disorder	HTR1A	targetBased	Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	61606	416
psychiatricDisorder	major depressive disorder	HTR1A	targetBased	Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	64908	366
immune	autoimmune disorder of the nervous system	S1PR1	targetBased	Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	55710	315
		TRPC4	targetBased	Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).	TRPC4	304001	1189
biologicalProcess	toolCompounds	KCNK9_blockers	targetBased	Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9	305610	3794
cardioVascular	arterial disorder	KCNK3	targetBased	Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	339674	2841
nervousSystem	neurodegeneration	SLC5A7	targetBased	Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT)	SLC5A7	306502	2634
visualSystem	eye disease	SLC5A7	targetBased	Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT)	SLC5A7	306502	1509
		TRPC4	targetBased	Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).	TRPC4	305600	1510
nervousSystem	hearing disorder	S1PR2	targetBased	Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	96879	207
nervousSystem	hearing disorder	S1PR2	targetBased	Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	96879	447
immune	psoriasis	ANO1_inhibitors	targetBased	Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A)	ANO1	306502	3633
		MGRG2	targetBased	Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling	MGRG2	306502	3868
		MGRG2	targetBased	Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling	MGRG2	306502	1932
respiratory	pulmonary arterial hypertension	ANO1_activators	targetBased	Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A)	ANO1	335180	1022
		MGRG2	targetBased	Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling	MGRG2	306502	1351
biologicalProcess	proteinMisfolding	PERK_inhibitors	targetBased	Primary cell-based high-throughput screening assay to measure PERK inhibition	EIF2AK3	217959	370
nervousSystem	neurodegeneration	Heat shock 70kDa protein 1A	pathwayBased	Primary cell-based high-throughput screening assay to identify transcriptional activators of heat shock protein 70 (Hsp70)	HSP70	196176	82
cancer	neoplastic disease or syndrome	GALR2_antagonists	targetBased	Primary cell-based high-throughput screening assay to identify antagonists of Galanin Receptor 2 (GALR2)	GALR2	140088	548
		TRPN1	targetBased	Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel N1 (TRPN1)	TRPN1	217959	390
nervousSystem	neurodegeneration	MCOLN3	targetBased	Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel ML3 (TRPML3)	MCOLN3	217959	632
cancer	neoplastic disease or syndrome	GALR2	targetBased	Primary cell-based high-throughput screening assay to identify agonists of Galanin Receptor 2 (GALR2)	GALR2	140088	678
cancer	neoplastic disease or syndrome	NPY2R	targetBased	Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y2	NPY2R	217959	969
psychiatricDisorder	mental process	NPY1R	targetBased	Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y1	NPY1R	217959	798
immune	immunomodulation	inhibitors of TLR4-MyD88 binding	phenotypic	Primary cell-based high-throughput screening assay for inhibitors of TLR4-MyD88 binding		195980	357
antiMicrobial	malaria	Inhibitors of Mosquito Biting Behavior	targetBased	Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior]	NPYLR7	265113	400
cardioVascular	Rare genetic cardiac disease	KCNH2	targetBased	Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	305610	1552
psychiatricDisorder	cognitive disorder	RGS4	targetBased	Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4)	RGS4	305610	2820
cardioVascular	congenital heart disease	KCNQ1	targetBased	Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	305610	1082
nervousSystem	Rare genetic epilepsy	KCNQ2	targetBased	Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	305600	1644
muculoEskeletalConnective	familial periodic paralysis	KCNJ2	targetBased	Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	305610	2592
psychiatricDisorder	cognitive disorder	RGS4	targetBased	Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of G-protein signaling 4 (RGS4)	RGS4	305610	1365
nervousSystem	Rare genetic epilepsy	KCNQ2	targetBased	Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	305609	3405
cardioVascular	congenital heart disease	KCNQ1	targetBased	Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	305610	3878
		TRPC4	targetBased	Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4)	TRPC4	305600	1291
psychiatricDisorder	anxiety	NPY1R	targetBased	Primary cell-based high-throughput screening assay for antagonists of NPY-Y1	NPY1R	196176	1984
immune	immunomodulation	STAT3	pathwayBased	Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	194666	1722
immune	immunomodulation	STAT3	pathwayBased	Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	194666	1772
immune	Primary immunodeficiency due to a defect in innate immunity	STAT1	targetBased	Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	195980	695
immune	immunomodulation	STAT1 activation	pathwayBased	Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1	195980	5134
cancer	neoplastic disease or syndrome	KLF5	targetBased	Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5)	KLF5	290726	671
nervousSystem	neurodegeneration	WEE1	targetBased	Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation	WEE1	217959	2616
nervousSystem	intellectual developmental disorder with or without epilepsy or cerebellar ataxia	RORA	pathwayBased	Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	64908	278
geneticDisorder	developmental defect during embryogenesis	NR5A1	targetBased	Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	64908	359
nervousSystem	intellectual developmental disorder with or without epilepsy or cerebellar ataxia	RORA	pathwayBased	Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	64908	979
geneticDisorder	developmental defect during embryogenesis	NR5A1	targetBased	Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	64908	1225
cancer	neoplastic disease or syndrome	JAK2	targetBased	Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	217959	2390
		S1PR4	targetBased	Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	217959	569
		S1PR4	targetBased	Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	217959	771
cancer	neoplastic disease or syndrome	NPY2R	targetBased	Primary cell based high-throughput screening assay for antagonists of neuropeptide Y receptor Y2 (NPY-Y2)	NPY2R	140088	1384
psychiatricDisorder	cognitive disorder	HTR1E	targetBased	Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	64908	641
psychiatricDisorder	cognitive disorder	HTR1E	targetBased	Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	64908	446
nervousSystem	neurodegeneration	VCP	targetBased	Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition	VCP	217959	923
antiViral	HIV	HIV type 1	targetBased	Primary biochemical high-throughput screening assay for inhibitors of the HIV Rev RRE RNA interaction (disruption of protein-RNA interaction)	REV	96879	769
cancer	neoplastic disease or syndrome	MAPK10	targetBased	Primary biochemical high-throughput screening assay for inhibitors of the c-Jun N-Terminal Kinase 3 (JNK3)	MAPK10	59788	366
visualSystem	eye disease	ROCK2	targetBased	Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	59788	212
nervousSystem	neurodegeneration	PTK2	targetBased	Primary biochemical high-throughput screening assay for inhibitors of Focal Adhesion Kinase (FAK)	PTK2	96879	811
antiBacterial	P. aeruginosa	Pseudomonas aeruginosa	targetBased	Primary biochemical high throughput screening assay to identify inhibitors of VIM-2 metallo-beta-lactamase	BLAVIM-2	290726	2575
		RBBP9	targetBased	Primary biochemical high throughput screening assay to identify inhibitors of Retinoblastoma binding protein 9 (RBBP9)	RBBP9	217959	445
biologicalProcess	apoptosis	BCL2L1_modulators	targetBased	Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).	BCL2L1	314998	2199
metabolicEndocrine	endocrine pancreas disorder	PPARG	targetBased	Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	196177	519
metabolicEndocrine	endocrine pancreas disorder	PPARG	targetBased	Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	196176	670
metabolicEndocrine	endocrine pancreas disorder	PPARG	targetBased	Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	196177	811
nervousSystem	neurodegeneration	PRMT1	targetBased	Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1)	PRMT1	369953	4757
antiBacterial	E. coli	Escherichia coli ΔtolC mutations	phenotypic	Primary Antimicrobial Assay for E. coli BW25113 âˆ†tolC::kan Protocol for 384-well HTS		65096	1420
antiViral	Dengue	Dengue virus type 2	targetBased	Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition	P29991	338623	1013
antiViral	SARS-CoV	SARS-CoV	pathwayBased	PLP&3CLP proteasesPChem screens plus phenotypic records @ ChEMBL	PLP&3CLP proteases
antiBacterial	luminous vibriosis	Vibrio harveyi (Beneckea harveyi)	targetBased	Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System	LUXP	302177	1222
antiMicrobial	malaria	Plasmodium falciparum Dd2	phenotypic	Plasmodium falciparum Dd2 Sybr green parasite growth Measured in Cell-Based and Microorganism Combination System Using Plate Reader		93079	2144
antiFungal	fungusGeneral	antifungal efflux pumps inhibitors	phenotypic	Phenotypic HTS multiplex for antifungal efflux pump inhibitors		328897	1437
antiBacterial	Campylobacter jejuni	Campylobacter jejuni	targetBased	PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity	WLAI	355889	350
gastroIntestinal	intestinal disease	OTUD3	targetBased	OTUD3 deubiquitinase inhibition: Primary qHTS	OTUD3	47480	334
cancer	cancerGeneral	nrf2Inhibitors	targetBased	Nrf2 qHTS screen for inhibitors	NFE2L2	360873	7438
cardioVascular	hypertension	sEH_inhibitors	targetBased	Novel sEH inhibitors for the therapeutic treatment of hypertension and inflammation	EPHX2	90640	310
antiMicrobial	malaria	P. falciparum erythrocyte W2	phenotypic	NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay		5608	4612
antiMicrobial	malaria	P. Falciparum erythrocyte 3D7	phenotypic	NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay		5608	4205
antiViral	Measles	Measles Virus	phenotypic	Non-Nucleoside Inhibitor of Measles Virus RNA-Dependent RNA Polymerase Complex Activity HTS Single Point (MLSMR Library)		137777	2077
cancer	cancerWithAlterationsInDnaRepair	yeastScreenWithAlterationsInDnaRepair	phenotypic	NCI Yeast Anticancer Drug Screen. Data for the sgs1 mgt1 strain		80498	9555
cancer	cancerWithAlterationsInDnaRepair	yeastScreenWithAlterationsInDnaRepair	phenotypic	NCI Yeast Anticancer Drug Screen. Data for the rad50 strain		81133	9814
cancer	cancerWithAlterationsInDnaRepair	yeastScreenWithAlterationsInDnaRepair	phenotypic	NCI Yeast Anticancer Drug Screen. Data for the mlh1 rad18 strain		81112	10175
cancer	cancerWithAlterationsInDnaRepair	yeastScreenWithAlterationsInDnaRepair	phenotypic	NCI Yeast Anticancer Drug Screen. Data for the mec2-1 strain		81133	8837
cancer	cancerWithAlterationsInDnaRepair	yeastScreenWithAlterationsInDnaRepair	phenotypic	NCI Yeast Anticancer Drug Screen. Data for the cln2 rad14 strain		80498	8083
cancer	cancerWithAlterationsInDnaRepair	yeastScreenWithAlterationsInDnaRepair	phenotypic	NCI Yeast Anticancer Drug Screen. Data for the bub3 strain		80504	9618
cancer	leukemia	leukemia	phenotypic	NCI In Vivo Anticancer Drug Screen. Data for tumor model P388 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice		44527	2353
cancer	leukemia	leukemia	phenotypic	NCI In Vivo Anticancer Drug Screen. Data for tumor model L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice		55741	1560
cancer	renalCancer	renalCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line		74677	3544
cancer	renalCancer	renalCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line		52726	2935
cancer	melanoma	melanoma	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the UACC-257 Melanoma cell line		71797	2912
cancer	melanoma	melanoma	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the UACC-257 Melanoma cell line		52717	2210
cancer	melanoma	melanoma	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the UACC-62 Melanoma cell line		74782	3675
cancer	melanoma	melanoma	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the UACC-62 Melanoma cell line		52399	3598
cancer	glioblastoma	glioblastoma	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the U251 Central Nervous System cell line		73184	3470
cancer	CNS_tumor	CNS_tumor	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the U251 Central Nervous System cell line		53211	3544
cancer	renalCancer	renalCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the TK-10 Renal cell line		74445	2716
cancer	renalCancer	renalCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the TK-10 Renal cell line		52047	1986
cancer	breastCancer	breastCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the T-47D Breast cell line		72767	3276
cancer	breastCancer	breastCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the T-47D Breast cell line		38148	2490
cancer	colonCancer	colonCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the SW-620 Colon cell line		75327	3576
cancer	colonCancer	colonCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the SW-620 Colon cell line		53508	4024
cancer	leukemia	leukemia	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the SR Leukemia cell line		67113	5428
cancer	leukemia	leukemia	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the SR Leukemia cell line		44307	5398
cancer	CNS_tumor	CNS_tumor	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the SNB-75 Central Nervous System cell line		73093	3359
cancer	CNS_tumor	CNS_tumor	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the SNB-75 Central Nervous System cell line		49685	3444
cancer	CNS_tumor	CNS_tumor	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the SNB-19 Central Nervous System cell line		74208	1576
cancer	CNS_tumor	CNS_tumor	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the SNB-19 Central Nervous System cell line		52778	2515
cancer	renalCancer	renalCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line		74708	2495
cancer	renalCancer	renalCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line		52967	3005
cancer	ovarianCancer	ovarianCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the SK-OV-3 Ovarian cell line		73297	2087
cancer	ovarianCancer	ovarianCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the SK-OV-3 Ovarian cell line		51081	2532
cancer	melanoma	melanoma	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-28 Melanoma cell line		74869	2694
cancer	melanoma	melanoma	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-28 Melanoma cell line		52593	1983
cancer	melanoma	melanoma	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line		73327	4240
cancer	melanoma	melanoma	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line		52438	3585
cancer	melanoma	melanoma	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-2 Melanoma cell line		70939	2926
cancer	melanoma	melanoma	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-2 Melanoma cell line		50295	2412
cancer	CNS_tumor	CNS_tumor	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line		74520	4513
cancer	CNS_tumor	CNS_tumor	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line		50511	3547
cancer	CNS_tumor	CNS_tumor	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the SF-295 Central Nervous System cell line		72353	3611
cancer	CNS_tumor	CNS_tumor	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the SF-295 Central Nervous System cell line		53205	3526
cancer	CNS_tumor	CNS_tumor	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the SF-268 Central Nervous System cell line		75289	2115
cancer	CNS_tumor	CNS_tumor	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the SF-268 Central Nervous System cell line		52931	2856
cancer	renalCancer	renalCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the RXF 393 Renal cell line		71215	4339
cancer	renalCancer	renalCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the RXF 393 Renal cell line		48061	3402
cancer	leukemia	leukemia	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the RPMI-8226 Leukemia cell line		70780	4886
cancer	leukemia	leukemia	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the RPMI-8226 Leukemia cell line		49781	4206
cancer	prostateCancer	prostateCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the PC-3 Prostate cell line		73700	2603
cancer	prostateCancer	prostateCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the PC-3 Prostate cell line		40498	3034
cancer	ovarianCancer	ovarianCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the OVCAR-8 Ovarian cell line		74586	2891
cancer	ovarianCancer	ovarianCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the OVCAR-8 Ovarian cell line		53426	3114
cancer	ovarianCancer	ovarianCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the OVCAR-5 Ovarian cell line		75004	1854
cancer	ovarianCancer	ovarianCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the OVCAR-5 Ovarian cell line		52502	2104
cancer	ovarianCancer	ovarianCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the OVCAR-4 Ovarian cell line		73088	2443
cancer	ovarianCancer	ovarianCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the OVCAR-4 Ovarian cell line		50969	2336
cancer	ovarianCancer	ovarianCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the OVCAR-3 Ovarian cell line		74864	4915
cancer	ovarianCancer	ovarianCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the OVCAR-3 Ovarian cell line		51983	3749
cancer	breastCancer	breastCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the NCI/ADR-RES Breast cell line		74972	2944
cancer	breastCancer	breastCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the NCI/ADR-RES Breast cell line		40779	2492
cancer	nonSmallCellLungCarcinoma	nonSmallCellLungCarcinoma	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the NCI-H522 Non-Small Cell Lung cell line, single concentration		71275	5229
cancer	nonSmallCellLungCarcinoma	nonSmallCellLungCarcinoma	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the NCI-H522 Non-Small Cell Lung cell line		48987	4260
cancer	nonSmallCellLungCarcinoma	nonSmallCellLungCarcinoma	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the NCI-H460 Non-Small Cell Lung cell line, single concentration		75211	4608
cancer	nonSmallCellLungCarcinoma	nonSmallCellLungCarcinoma	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the NCI-H460 Non-Small Cell Lung cell line		52033	4098
cancer	nonSmallCellLungCarcinoma	nonSmallCellLungCarcinoma	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the NCI-H322M Non-Small Cell Lung cell line, single concentration		73050	1747
cancer	nonSmallCellLungCarcinoma	nonSmallCellLungCarcinoma	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the NCI-H322M Non-Small Cell Lung cell line		52046	2317
cancer	nonSmallCellLungCarcinoma	nonSmallCellLungCarcinoma	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the NCI-H226 Non-Small Cell Lung cell line, single concentration		72375	2184
cancer	nonSmallCellLungCarcinoma	nonSmallCellLungCarcinoma	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the NCI-H226 Non-Small Cell Lung cell line		49564	2467
cancer	nonSmallCellLungCarcinoma	nonSmallCellLungCarcinoma	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line, single concentration		75010	2580
cancer	nonSmallCellLungCarcinoma	nonSmallCellLungCarcinoma	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line		53214	3094
cancer	leukemia	leukemia	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the MOLT-4 Leukemia cell line		73777	4676
cancer	leukemia	leukemia	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the MOLT-4 Leukemia cell line		52219	4310
cancer	breastCancer	breastCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-435 Breast cell line		75071	5500
cancer	breastCancer	breastCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-435 Breast cell line		40193	3548
cancer	breastCancer	breastCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-231/ATCC Breast cell line		74706	3330
cancer	breastCancer	breastCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-231/ATCC Breast cell line		40090	2464
cancer	breastCancer	breastCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the MCF7 Breast cell line		75981	4212
cancer	breastCancer	breastCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the MCF7 Breast cell line		40400	4425
cancer	melanoma	melanoma	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line		71882	3760
cancer	melanoma	melanoma	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line		49416	2812
cancer	melanoma	melanoma	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the M14 Melanoma cell line		73968	4221
cancer	melanoma	melanoma	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the M14 Melanoma cell line		52257	3432
cancer	melanoma	melanoma	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the LOX IMVI Melanoma cell line		73462	4776
cancer	melanoma	melanoma	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the LOX IMVI Melanoma cell line		50080	3993
cancer	colonCancer	colonCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the KM12 Colon cell line		75218	3369
cancer	colonCancer	colonCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the KM12 Colon cell line		53104	3462
cancer	leukemia	leukemia	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the K-562 Leukemia cell line		71880	4980
cancer	leukemia	leukemia	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the K-562 Leukemia cell line		51855	4709
cancer	ovarianCancer	ovarianCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the IGROV1 Ovarian cell line		72867	3166
cancer	ovarianCancer	ovarianCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the IGROV1 Ovarian cell line		52609	3249
cancer	colonCancer	colonCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the HT29 Colon cell line		74688	5101
cancer	colonCancer	colonCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the HT29 Colon cell line		52844	3773
cancer	breastCancer	breastCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the HS 578T Breast cell line		71841	2560
cancer	breastCancer	breastCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the HS 578T Breast cell line		38502	2659
cancer	nonSmallCellLungCarcinoma	nonSmallCellLungCarcinoma	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line		65189	3616
cancer	nonSmallCellLungCarcinoma	nonSmallCellLungCarcinoma	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line		47537	3298
cancer	nonSmallCellLungCarcinoma	nonSmallCellLungCarcinoma	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the HOP-62 Non-Small Cell Lung cell line		73643	2556
cancer	nonSmallCellLungCarcinoma	nonSmallCellLungCarcinoma	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the HOP-62 Non-Small Cell Lung cell line		52001	2981
cancer	leukemia	leukemia	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line		71675	5995
cancer	leukemia	renalCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line		48426	4751
cancer	colonCancer	colonCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the HCT-116 Colon cell line		75551	5013
cancer	colonCancer	colonCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the HCT-116 Colon cell line		52727	4422
cancer	colonCancer	colonCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the HCT-15 Colon cell line		75530	3437
cancer	colonCancer	colonCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the HCT-15 Colon cell line		53050	3475
cancer	colonCancer	colonCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the HCC-2998 Colon cell line		72852	3007
cancer	colonCancer	colonCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the HCC-2998 Colon cell line		48421	2752
cancer	nonSmallCellLungCarcinoma	nonSmallCellLungCarcinoma	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the EKVX Non-Small Cell Lung cell line, single concentration		64389	1626
cancer	nonSmallCellLungCarcinoma	nonSmallCellLungCarcinoma	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the EKVX Non-Small Cell Lung cell line		50820	2137
cancer	prostateCancer	prostateCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line		74776	2861
cancer	prostateCancer	prostateCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line		40598	2824
cancer	colonCancer	colonCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the COLO 205 Colon cell line		72743	4943
cancer	colonCancer	colonCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the COLO 205 Colon cell line		52712	3480
cancer	leukemia	leukemia	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the CCRF-CEM Leukemia cell line		70489	4627
cancer	leukemia	leukemia	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the CCRF-CEM Leukemia cell line		50580	5047
cancer	renalCancer	renalCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the CAKI-1 Renal cell line		68322	2874
cancer	renalCancer	renalCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the CAKI-1 Renal cell line		50188	3283
cancer	breastCancer	breastCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the BT-549 Breast cell line		71655	2694
cancer	breastCancer	breastCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the BT-549 Breast cell line		37232	2330
cancer	renalCancer	renalCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line		74545	3244
cancer	renalCancer	renalCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line		52894	3233
cancer	nonSmallCellLungCarcinoma	nonSmallCellLungCarcinoma	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line, single concentration		74386	2485
cancer	nonSmallCellLungCarcinoma	nonSmallCellLungCarcinoma	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line		53560	2992
cancer	renalCancer	renalCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the A498 Renal cell line		69851	3516
cancer	renalCancer	renalCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the A498 Renal cell line		47090	3449
cancer	renalCancer	renalCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the 786-0 Renal cell line		74688	3319
cancer	renalCancer	renalCancer	phenotypic	NCI human tumor cell line growth inhibition assay. Data for the 786-0 Renal cell line		52428	3081
antiViral	HIV	HIV type 1	phenotypic	NCI AIDS Antiviral Assay		41976	1527
cardioVascular	congestive heart failure	NPR1	targetBased	Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	76168	1231
antiBacterial	tuberculosis	Mycobacterium tuberculosis	targetBased	Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity	BioA	353572	342
otherPhenotypes	circadian rhythm	RGS16	targetBased	Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.	RGS16	218528	826
nervousSystem	Mendelian neurodevelopmental disorder	GNAO1	targetBased	Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.	GNAO1	218528	750
nervousSystem	Mendelian neurodevelopmental disorder	GNAO1	targetBased	Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.	GNAO1	218528	770
nervousSystem	Mendelian neurodevelopmental disorder	GNAO1	targetBased	Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.	GNAO1	218528	711
biologicalProcess	apoptosis	BCL2A1_modulators	targetBased	Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bfl-1	BCL2A1	194826	237
		RPL19B	pathwayBased	Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.	RPL19B	325372	982
		MEP2	pathwayBased	Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.	MEP2	326651	1682
cancer	cancerGeneral	mTOR_pathwayModulators	pathwayBased	Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.	APE1	324734	1090
cancer	cancerGeneral	mTOR_pathwayModulators	pathwayBased	Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.	CIT2	321534	210
cancer	neoplastic disease or syndrome	MAP3K3	targetBased	Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype	MAP3K3	289573	4159
nervousSystem	neurodegeneration	MAP4K2	targetBased	Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant	MAP4K2	289539	1003
nervousSystem	neurodegeneration	MAP4K2	targetBased	Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype	MAP4K2	289465	3276
immune	autoimmuneDisorders	cGAS_inhibitors	targetBased	mouse cGAS RapidFire screen	CGAS	123258	226
immune	autoimmuneDisorders	cGAS_inhibitors	targetBased	mouse cGAS chemiluminescence screen	CGAS	160326	237
reproductiveSystem	male reproductive system disease	PTGER2	targetBased	Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	255537	2141
biologicalProcess	secretionPath	Modulators of Post-Golgi Transport	phenotypic	Modulators of Post-Golgi Transport		97509	875
nervousSystem	epilepsy	AMPAStargazinComplexModulators	targetBased	Modulation of AMPAR-stargazin complexes	CACNG2	40473	1400
antiBacterial	S. Pneumoniae	Streptococcus pyogenes serotype M1	targetBased	MLPCN Streptokinase Expression Inhibition	SKA	303477	3959
		SIRT5	targetBased	MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5	SIRT5	323507	3752
hematologic	thrombosis	plateletActivationInhibitors	phenotypic	MLPCN Platelet Activation -Dense Granule Release		302451	661
biologicalProcess	Oxidative Metabolic Function	PGC1aInhibitors	phenotypic	MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity		345870	601
biologicalProcess	Oxidative Metabolic Function	PGC1aActivators	phenotypic	MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity		345870	740
		MEX-5	targetBased	MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen	MEX-5	301788	1137
immune	autoimmuneDisorders	ERAP1_inhibitors	targetBased	MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity	ERAP1	335777	499
nervousSystem	PD	aSynucleinExpressionInhibitors	phenotypic	MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors		303801	2498
biologicalProcess	synucleinEffect	aSynucleinExpressionActivators	phenotypic	MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators		303801	21690
cancer	neoplastic disease or syndrome	MITF	targetBased	MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	331360	2760
cancer	melanoma	MITF_expressionEnhancers	phenotypic	MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity		300845	2272
metabolicEndocrine	endocrine pancreas disorder	PPARG	targetBased	Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	99314	390
metabolicEndocrine	endocrine pancreas disorder	PPARG	targetBased	Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	196176	782
metabolicEndocrine	endocrine pancreas disorder	PPARG	targetBased	Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	99314	335
muculoEskeletalConnective	bone disease	MMP14	targetBased	Luminescent HTS for small molecule inhibitors of MT1-MMP transcription	MMP14	86733	537
metabolicEndocrine	T2diabetes	Glucose-dependent insulin secretion	phenotypic	Luminescent GLuc Reporter Gene Assay Primary HTS to Identify Small Molecule Activator of Glucose Dependent Insulin Secretion Measured in Cell-Based System Using Plate Reader - 7055-01_Activator_SinglePoint_HTS_Activity		371108	2287
metabolicEndocrine	cholesterolLevels	ALPI_activators	targetBased	Luminescent assay for identification of activators of bovine intestinal alkaline phosphatase	ALPI	195570	326
immune	immunomodulation	ALPG_activators	targetBased	Luminescent assay for HTS discovery of chemical activators of placental alkaline phosphatase	ALPG	95729	1178
nervousSystem	palsy	NR0B1	targetBased	Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)	NR0B1	343468	3417
immune	immunomodulation	AHR_activators	targetBased	Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR	324747	7988
cancer	cancerGeneral	HSP90AA1	targetBased	Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90)	HSP90AA1	290726	2649
cancer	neoplastic disease or syndrome	NR5A2	targetBased	Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2)	NR5A2	363803	458
cancer	neoplastic disease or syndrome	OPRM1	targetBased	Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	335239	695
		NCOA3	targetBased	Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3)	NCOA3	359207	620
cancer	neoplastic disease or syndrome	NCOA2	targetBased	Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2)	NCOA2	368927	620
cancer	neoplastic disease or syndrome	NCOA1	targetBased	Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1)	NCOA1	359206	428
metabolicEndocrine	insulinSensitization	NR2F2	targetBased	Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2)	NR2F2	369953	2602
metabolicEndocrine	Energy balance, obesity	MC4R	targetBased	Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	356160	3470
psychiatricDisorder	developmental disorder of mental health	HTR2A	targetBased	Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	363803	2412
antiHelminthic	H. glycines	DAF-12_activators	targetBased	Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).	DAF-12	369953	6837
cancer	neoplastic disease or syndrome	OPRM1	targetBased	Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	335239	991
nervousSystem	neurodegeneration	HEL111	pathwayBased	Luminescence-based cell-based primary high throughput screening assay to identify activators of Transthyretin (TTR) transcription	HEL111	91909	1155
muculoEskeletalConnective	Friedreich ataxia	FXN	targetBased	Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter	FXN	356160	1985
geneticDisorder	Rare genetic developmental defect during embryogenesis	SMARCA2	targetBased	Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)	SMARCA2	368927	3838
antiHelminthic	S. stercoralis	DAF-12_activators	targetBased	Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12)	DAF-12	369953	3700
antiHelminthic	H. contortus	DAF-12_activators	targetBased	Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12)	DAF-12	369953	5353
nervousSystem	palsy	NR0B1	targetBased	Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1	NR0B1	368927	4094
nervousSystem	neurodegeneration	NR2E3	targetBased	Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)	NR2E3	362026	1281
antiMicrobial	trypanosomiasis	met-tRNA synt	targetBased	Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS)	3662741	363803	1456
metabolicEndocrine	obesity, diabetes, and cardiovascular disease	PLIN5	targetBased	Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)	PLIN5	363803	2851
		STK33	targetBased	Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine Kinase 33 Activity	STK33	321808	235
psychiatricDisorder	mental or behavioural disorder	GSK3A	targetBased	Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	315412	318
antiMicrobial	chagas	T. Cruzi replication	phenotypic	Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication		303218	4394
cardioVascular	ischemia	HIF_expressionActivators	phenotypic	Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway		300341	950
cancer	EwingSarcoma	EWS/Fli transcriptional activity inhibitors	phenotypic	Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity		342236	2318
		STK33	targetBased	Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33	STK33	37341	2812
cancer	neoplastic disease or syndrome	HSF1	targetBased	Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).	HSF1	301324	2328
cancer	breastCancer	breastCancerStemCellsCadherinNull	phenotypic	Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells		300621	3187
metabolicEndocrine	T1Diabetes	b cell apoptosis	phenotypic	Luminescence Cell-Based Primary HTS to Identify Inhibitors of Beta Cell Apoptosis.		303500	2435
biologicalProcess	apoptosis	BCL2L11_inhibitors	targetBased	Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11	325630	216
geneticDisorder	Rare genetic developmental defect during embryogenesis	YAP1	targetBased	Luminescence cell-based high throughput primary assay to identify inhibitors of TEAD-YAP interaction.	YAP1	639428	9218
biologicalProcess	SUMOylation	SUMOylationInhibitors	phenotypic	Luminescence Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301		318458	3322
cancer	cancerGeneral	NLG_inhibitors	phenotypic	Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2		358025	830
antiMicrobial	leishmaniasis	Leishmania promastigote	phenotypic	Leishmania major promastigote HTS		196141	17620
cancer	neoplastic disease or syndrome	KLK5	targetBased	Kallikrein 5 1536 HTS	KLK5	214187	1264
cancer	cancerGeneral	Her-Kinase Expression	phenotypic	Isolation of Inhibitors of Her-Kinase Expression - 66K library screen		64629	448
metabolicEndocrine	thyroid disease	TSHR	targetBased	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	329153	670
antiBacterial	plague	Yersinia pestis	targetBased	Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity	SUPX	356253	229
nervousSystem	neurodegeneration	USP1	targetBased	Inhibitors of USP1/UAF1: Primary Screen	USP1	389569	904
metabolicEndocrine	nutritional deficiency disease	VDR	targetBased	Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	394050	3624
reproductiveSystem	male reproductive system disease	PTGER2	targetBased	Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	250190	1304
antiPrion	prionDisease	PrP_Inhibitors	phenotypic	Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity		334634	1167
antiMicrobial	malaria	Plasmodium falciparum (isolate 3D7)	targetBased	Inhibitors of Plasmodium falciparum M17- Family Leucine Aminopeptidase (M17LAP)	LAP	216988	827
antiMicrobial	malaria	Plasmodium falciparum (isolate 3D7)	targetBased	Inhibitors of Plasmodium falciparum M1- Family Alanyl Aminopeptidase (M1AAP)	M1AAP	216987	913
antiBacterial	tuberculosis	Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)	targetBased	Inhibitors of Mycobacterial Glucosamine-1-phosphate acetyl transferase (GlmU)	GLMU	215860	533
antiViral	EBV	Epstein-Barr virus	phenotypic	Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity	LMP1	345064	2373
cancer	cancerGeneral	Inhibitors of CDC25B-CDK2/CyclinA interaction	targetBased	Inhibitors of CDC25B-CDK2/CyclinA interaction	CCNA2	93798	679
nervousSystem	epilepsy	CACNA1H_inhibitors	targetBased	Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H	104728	4230
cancer	cancerGeneral	TROY_signalling_inhibitors	phenotypic	Inhibitor identification of TROY dependent signaling using uHTS single point assay		360657	3551
cancer	neoplastic disease or syndrome	MLLT3	targetBased	Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity	MLLT3	344459	1627
antiMicrobial	trypanosomiasis	Trypanosoma cruzi	phenotypic	Inhibition of T.cruzi proliferation in culture Measured in Cell-Based System Using Plate Reader - 2138-01_Inhibitor_SinglePoint_HTS_Activity		76537	4582
antiMicrobial	malaria	P. falciparum LDH	phenotypic	Inhibition of P. falciparum LDH		13456	0
antiMicrobial	malaria	P. falciparum Dd2	phenotypic	Inhibition of P. falciparum Dd2		13456	7921
antiMicrobial	malaria	P. falciparum 3d7	phenotypic	Inhibition of P. falciparum 3D7		13456	13456
immune	fibrosis	fibronectinDeposition	phenotypic	Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity		342865	297
antiMicrobial	malaria	Plasmodium falciparum (isolate 3D7)	phenotypic	In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity	811941	336519	2306
cancer	neoplastic disease or syndrome	GPR55	targetBased	Image-Based HTS for Selective Antagonists for GPR55	GPR55	291657	370
cancer	neoplastic disease or syndrome	NTSR1	targetBased	Image-Based HTS for Selective Agonists for NTR1	NTSR1	331753	556
immune	immunomodulation	NFkB_Translocation_inhibitors	phenotypic	IL-1B Induced NFkB Translocation - Primary Screen		94265	409
metabolicEndocrine	congenitalDiabetes	HNF4_binding_to_DNA_enhancers	targetBased	Identify inhibitors of HNF4 alpha protein binding to DNA	NR2A1	363839	1098
antiViral	HIV	HIV type 1	targetBased	Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity	VIF	335681	1162
antiViral	SV40	Simian virus 40 (SV40)	targetBased	Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents	P03070	305355	1203
rareDiseases	cysticFibrosis	cftrCorrectors	targetBased	Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	CFTR	343786	1253
nervousSystem	monogenic epilepsy	SLC12A5	targetBased	Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen	SLC12A5	189132	4127
geneticDisorder	Pseudoxanthoma elasticum	ABCC1_activators	targetBased	Identification of Molecular Probes that Activate MRP-1	ABCC1	138717	842
cancer	neoplastic disease or syndrome	RAD54L	targetBased	Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity	RAD54L	358498	505
cancer	cancerGeneral	Chromobox protein homolog 7 inhibitors	targetBased	Identification of CBX7 inhibitors - Primary Alpha Screen	CBX7	64999	724
cancer	neoplastic disease or syndrome	SELE	targetBased	Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity	SELE	257988	963
		SDO1	targetBased	Identification and characterization of compounds for addressing human bone marrow failure	SDO1	138737	298
biologicalProcess	angiogenesis	angiogenesis_modulators_secondary	phenotypic	Human Lung Fibroblast Proliferation Assay		84879	937
cancer	smallCellLungCarcinoma	smallCellLungCarcinomaCellLineExpressingTransportDetoxProtMDR1	phenotypic	Human H69AR Lung Tumor Cell Growth Inhibition Assay - 86K Screen		85200	5142
biologicalProcess	angiogenesis	angiogenesis_modulators	phenotypic	Human Endothelial Cell Proliferation Assay in 384-well format		86159	925
immune	autoimmuneDisorders	cGAS_inhibitors	targetBased	human cGAS chemiluminescence screen	CGAS	281243	218
immune	fibrosis	ALR activators	targetBased	HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	GFER	288728	10857
cancer	cancer	ALR inhibitors	targetBased	HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	GFER	288728	10857
biologicalProcess	Lipid transport	SCARB1	targetBased	HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	319204	3065
		SCARB1	targetBased	HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	316970	306
cancer	neoplastic disease or syndrome	HRAS	targetBased	HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	194628	267
cancer	neoplastic disease or syndrome	RAC1	targetBased	HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype	RAC1	194628	521
cancer	neoplastic disease or syndrome	RAC1	targetBased	HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant	RAC1	194629	219
		RAB2A	targetBased	HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab2 wildtype	RAB2A	194628	365
biologicalProcess	RAS_pathways	RAS_inhibitors	phenotypic	HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Cdc42 wildtype		194628	398
biologicalProcess	necrosis	necrosisByCaspaseInhibitors	phenotypic	HTS to identify inhibitors of zVAD Induced Cell Death in L929 Cells.		217101	832
cancer	leukemia	HOXA9	pathwayBased	HTS to identify compounds that promote myeloid differentiation with MLPCN compound set	HOXA9	358556	3721
immune	pemphigus	pemphigusAntibodiesInhibitors	phenotypic	HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies		311344	1495
antiFungal	antifungal	VMA11	targetBased	HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin	VMA11	345985	1287
immune	fibrosis	SMAD3	targetBased	HTS of Smad transcription factor inhibitors	SMAD3	88033	251
reproductiveSystem	menopauseSymptoms	ESR1_modulators	targetBased	HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1	86095	1151
cancer	breastCancer	ESR1_inhibitors	targetBased	HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1	86095	1442
cancer	neoplastic disease or syndrome	SENP8	targetBased	HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8)	SENP8	330392	4119
immune	immune deficiency disease	ITGB2	targetBased	HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	92518	501
metabolicEndocrine	disorder of glycosylation	MPI	targetBased	HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.	MPI	194152	814
metabolicEndocrine	disorder of glycosylation	MPI	targetBased	HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate	MPI	194152	1288
metabolicEndocrine	disorder of glycosylation	MPI	targetBased	HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat	MPI	194152	656
cancer	cancerGeneral	HSP90 known inhibitor displacement	targetBased	HTS for Tumor Hsp90 Inhibitors	HSP90AA1	63696	220
antiMicrobial	cryptococcosis	Cryptococcus neoformans	targetBased	HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity	AK	357997	735
muculoEskeletalConnective	myotoxicity	C2C12_myopathy	phenotypic	HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity		329274	2586
biologicalProcess	apoptosis	DDIT3_inhibitors	targetBased	HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress	DDIT3	218654	8241
metabolicEndocrine	thyroid disease	PAX8	targetBased	HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity	PAX8	353950	4145
nervousSystem	neurodegeneration	HP1-betaChromodomainInteractionsInhibitors	targetBased	HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails	CBX1	383363	2142
muculoEskeletalConnective	muscularDystrophy	DUX4_inhibitors	targetBased	HTS for inhibitors of DUX4-mediated transcriptional activation	DUX4	36365	289
cardioVascular	hypertension	CACNA1D_inhibitors	targetBased	HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D	335531	328
gastroIntestinal	intestinal disease	ITGA4	targetBased	HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	326888	645
cancer	breastCancer	ESR2_inhibitors	targetBased	HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2	86095	1114
dermatology	skin disease	ITGAL	targetBased	HTS for developing T Cell Immune Modulators	ITGAL	326271	221
immune	asthma	ADRB2_activators	targetBased	HTS for Beta-2AR agonists via FAP method	ADRB2	339297	1446
cancer	cancerGeneral	BAP1_inhibitors	targetBased	HTS for BAP1 Enzyme inhibitors	BAP1	71016	346
antiBacterial	E. coli	Escherichia coli ribosomal RNAs	phenotypic	HTS for Bacterial rRNA inhibitors Measured in Microorganism-Based System Using Plate Reader - 7056-01_Inhibitor_SinglePoint_HTS_Activity		348128	5500
nervousSystem	monogenic epilepsy	YWHAG	targetBased	HTS for 14-3-3 protein interaction modulators	YWHAG	157962	312
		PTPN7	targetBased	HTS Discovery of Chemical Inhibitors of HePTP, a Leukemia Target	PTPN7	112381	724
cancer	cancerGeneral	VHR1_inhibitors	targetBased	HTS Colorimetric assay for the identification of compounds that inhibit VHR1	DUSP3	49813	347
nervousSystem	PD	D2_PAMs	targetBased	HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	DRD2	339887	1178
cancer	cancerGeneral	PPP1R15A	targetBased	HTS Assay for Peg3 Promoter Inhibitors	PPP1R15A	359244	6145
antiMicrobial	trypanosomiasis	Trypanosoma brucei brucei (strain 927/4 GUTat10.1)	targetBased	HTS assay for inhibitors of Trypanosoma brucei hexokinase 1	3663016	220222	239
cancer	cancerGeneral	AKT1_inhibitors	targetBased	HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1	356517	1139
metabolicEndocrine	Abnormality of metabolism/homeostasis	TRPV1	targetBased	HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	316642	617
nervousSystem	psychosis	D2_antagonists	targetBased	HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	DRD2	336308	6862
nervousSystem	PD	D2_agonists	targetBased	HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	DRD2	335652	1779
biologicalProcess	cytochromesRoles	CYP2C9_activators	targetBased	HTS Assay for Activators of Cytochrome P450 2A9	CYP2C9	95858	1368
nervousSystem	pain	CACNA1B_modulators	targetBased	Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B	292323	567
antiViral	HIV	HIV type 1	targetBased	HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.	TAR	103073	615
antiViral	HIV	HIV type 1	targetBased	HIV-1 RT-RNase H MLSCN HTS MH077605	GAG-POL	65218	1250
antiViral	HIV	HIV type 1	targetBased	HIV-1 RNase H Inhibition	GAG-POL	99768	769
antiViral	HIV	HIV fussion	phenotypic	HIV entry: Env-mediated Cell Fusion Measured in Cell-Based System Using Plate Reader - 7013-01_Inhibitor_SinglePoint_HTS_Activity		354822	3866
cardioVascular	myocardialFibrosis	GC-B_PAMs	phenotypic	High-throughput screening primary assay to identify small molecule activators of human guanylyl cyclase B (GC-B) receptor activity		370293	399
cardioVascular	hypertension	GC-A_PAMs	phenotypic	High-throughput screening primary assay to identify small molecule activators of human GC-A enzyme activity		370293	519
nervousSystem	hearing disorder	MARVELD2	targetBased	High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity	MARVELD2	362274	1085
geneticDisorder	ear malformation	GNAI3	targetBased	High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits	GNAI3	204125	876
antiBacterial	anthrax	Bacillus anthracis Lethal factor inhibitors	targetBased	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	P15917	354794	422
antiBacterial	botulism	Clostridium botulinum toxin inhibitors	targetBased	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	BoNT/F	354794	780
antiBacterial	botulism	Clostridium botulinum (strain Hall / ATCC 3502 / NCTC 13319 / Type A)	targetBased	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	BOTA	354794	609
biologicalProcess	autophagy	autophagy imaging assay	phenotypic	High-content cell-based screening for modulators of autophagy		194528	1903
urinarySystem	focal segmental glomerulosclerosis	TRPC6	targetBased	High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6)	TRPC6	305610	3253
urinarySystem	focal segmental glomerulosclerosis	TRPC6	targetBased	High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6)	TRPC6	305610	382
antiViral	FMDV	Foot-and-mouth disease virus	phenotypic	High Throughput Screening for Foot and Mouth Disease Virus Antivirals		404062	5020
psychiatricDisorder	drug addiction	SLC6A3	targetBased	High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	108286	1415
antiBacterial	tuberculosis	Mycobacterium Tuberculosis	phenotypic	High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media		327558	1938
antiViral	HIV	HIV-VIF	targetBased	High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction	VIF	258750	1498
antiBacterial	tuberculosis	Mycobacterium tuberculosis H37Rv	phenotypic	High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv		215098	2044
cancer	colonCancer	colonCancerNotExpressingOncogenicBetaCatenin	phenotypic	High Throughput Screen to Identify Compounds that Suppress the Growth of Human Colon Tumor Cells Lacking Oncogenic Beta Catenin Expression		138737	2051
cancer	colonCancer	colonCancerwithPtenDeletion	phenotypic	High Throughput Screen to Identify Compounds that Suppress the Growth of Cells with a Deletion of the PTEN Tumor Suppressor		138417	1658
antiBacterial	Enterococcus faecalis	Enterococcus faecalis (Streptococcus faecalis)	targetBased	High Throughput Screen to Identify Compounds that Inhibit Class II HMG-CoA Reductases - Primary Screen	MVAE	194344	792
nervousSystem	neurodegeneration	NFKB1	pathwayBased	High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	193265	3100
antiBacterial	tuberculosis	Mycobacterium tuberculosis H37Rv	phenotypic	High Throughput Screen of 100,000 compound library to Identify Inhibitors of Mycobacterium tuberculosis H37Rv		100685	1594
antiBacterial	tuberculosis	Mycobacterium Tuberculosis	phenotypic	High throughput screen for small molecule inhibitors of a hypoxia-regulated fluorescent biosensor in Mycobacterium tuberculosis		300060	312
metabolicEndocrine	obesity	LipidDropletFormation	phenotypic	High Throughput Imaging Assay for Hepatic Lipid Droplet Formation		236434	954
biologicalProcess	dementia	betaCateninTranslocation	targetBased	High Throughput Imaging Assay for Beta-Catenin	CTNNB1	193542	587
urinarySystem	renal tubular transport disease	KCNJ1	targetBased	High throughput discovery of novel modulators of ROMK K+ channel activity: Primary Screen	KCNJ1	125268	2463
		PTBP1	targetBased	High Content Assay for Compounds that inhibit the Assembly of the Perinucleolar Compartment	PTBP1	139718	4338
biologicalProcess	stressResponse	HSF1_activators	targetBased	Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity	HSF1	301170	5173
biologicalProcess	proteinTransport	DyneinTransport	phenotypic	HCS to Identify Inhibitors of Dynein Mediated Cargo Transport on Microtubules.		219902	1036
metabolicEndocrine	insulinSignaling	InsulinPromoterDownRegulation	phenotypic	HCS for Compounds that Up-Regulate Insulin Promoter Activity in MIN6 Cells		192980	574
metabolicEndocrine	insulinSignaling	InsulinPromoterDownRegulation	phenotypic	HCS for Compounds that Down-Regulate Insulin Promoter Activity in MIN6 Cells		192372	925
dermatology	skin disease	TUBB	targetBased	HCS assay for microtubule stabilizers	TUBB	195821	1625
visualSystem	eye disease	GBA1	targetBased	Glucocerebrosidase	GBA1	48118	549
metabolicEndocrine	systolic blood pressure	RAD52	targetBased	FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2	RAD52	352074	1608
metabolicEndocrine	Energy balance, obesity	HCRTR1	targetBased	FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	326024	5748
antiBacterial	P. aeruginosa	Pseudomonas aeruginosa	targetBased	Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity	PvdQ	337500	213
antiMicrobial	malaria	Plasmodium falciparum	targetBased	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	Pf-apPOL	201181	519
otherPhenotypes	age at menarche	NPBWR1	targetBased	Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7).	NPBWR1	290726	3127
psychiatricDisorder	mental or behavioural disorder	OXTR	targetBased	Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	324747	1043
antiViral	HCV	Hepacivirus hominis	targetBased	Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3)	NS3	290726	1635
		PPP5C	targetBased	Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).	PPP5C	314999	564
biologicalProcess	endocannabinoidSignaling	DAGLB_inhibitors	targetBased	Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)	DAGLB	343468	202
antiViral	HCV	Hepacivirus hominis	targetBased	Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors: biochemical high-throughput screening assay to identify compounds that cause fluorescent intercalator displacement (FID)	NS3	290725	487
nervousSystem	neurodegeneration	CHRM1_PAMs	targetBased	Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1	359207	316
biologicalProcess	M4_AcChBiology	CHRM5	targetBased	Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	363803	1081
nervousSystem	AD	CHRM4_PAMs	targetBased	Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4	363803	1450
muculoEskeletalConnective	connective tissue disease	TLR9	targetBased	Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	343468	734
reproductiveSystem	male reproductive system disease	RIPK2	targetBased	Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2)	RIPK2	363803	1383
psychiatricDisorder	insomnia	HCRTR1	targetBased	Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	326024	1387
nervousSystem	PD	TAAR1	targetBased	Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1)	TAAR1	362577	5374
respiratory	respiratoryDisorders	CHRM1_antgonists	targetBased	Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1	359207	4555
biologicalProcess	M4_AcChBiology	CHRM5	targetBased	Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	363803	2133
nervousSystem	PD	CHRM4_antgonists	targetBased	Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4	363803	2629
psychiatricDisorder	anxiety	GALR3_antagonists	targetBased	Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the Galanin Receptor 3 (GalR3)	GALR3	357859	1562
psychiatricDisorder	schizophrenia	TAAR1	targetBased	Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1)	TAAR1	362577	3573
biologicalProcess	M4_AcChBiology	CHRM5	targetBased	Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	363803	698
nervousSystem	psychosis	CHRM4_agonists	targetBased	Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4	363803	502
nervousSystem	neurodegeneration	CHRM1_agonists	targetBased	Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1	359207	1189
nervousSystem	huntington	cagRnaRepeats	phenotypic	Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats		368927	4667
antiBacterial	tuberculosis	Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)	targetBased	Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis	FBA	359207	8215
muculoEskeletalConnective	hypertrophic cardiomyopathy	TNNI3	targetBased	Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	335238	390
muculoEskeletalConnective	hypertrophic cardiomyopathy	TNNI3	targetBased	Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	335239	801
immune	autoimmuneDisorders	TCR-CD3 interaction	phenotypic	Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe		362574	1343
antiViral	CCHFV	Crimean-Congo Hemorrhagic Fever (CCHF) virus	targetBased	Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate	vOTU	368927	2045
antiMicrobial	trypanosomiasis	Trypanosoma brucei brucei	targetBased	Fluorescence-based biochemical high throughput primary assay to identify inhibitors of Trypanosoma brucei RNA editing ligase 1 (TbREL1)	REL1	89157	438
biologicalProcess	toolCompoundsMultiDiseases	PLCG1	targetBased	Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	369953	3123
geneticDisorder	spondylometaphyseal dysplasia with corneal dystrophy	PLCB3	targetBased	Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).	PLCB3	369953	662
antiFungal	antifungal	TPT1	targetBased	Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).	TPT1	302663	2452
metabolicEndocrine	inborn disorder of amino acid transport	PREPL	targetBased	Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL)	PREPL	324747	2221
dermatology	skin disease	PLA2G7	targetBased	Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH)	PLA2G7	326024	4934
psychiatricDisorder	cerebral arteriopathy with subcortical infarcts and leukoencephalopathy	HTRA1	targetBased	Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	343467	1710
antiViral	EBV	Epstein-Barr virus	targetBased	Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).	BKRF1	302663	1022
nervousSystem	neurodegeneration	PPME1	targetBased	Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).	PPME1	314999	1683
muculoEskeletalConnective	connective tissue disease	PADI4	targetBased	Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS)	PADI4	326022	1334
nervousSystem	neurodegeneration	MCL1	targetBased	Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.	MCL1	314998	2139
psychiatricDisorder	pervasive developmental disorder	PAFAH1B3	targetBased	Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)	PAFAH1B3	335239	928
nervousSystem	neurodegeneration	PAFAH1B2	targetBased	Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)	PAFAH1B2	335239	4158
muculoEskeletalConnective	bone fracture related measurement	PAFAH2	targetBased	Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2)	PAFAH2	335239	3325
		GLD-1	targetBased	Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.	GLD-1	324746	1419
antiBacterial	E. coli	Escherichia coli (strain K12)	targetBased	Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon)	LON	362020	1524
geneticDisorder	genetic, familial or congenital disease	ABHD17B	targetBased	Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.	ABHD17B	302663	993
nervousSystem	neurodegeneration	GSTO1	targetBased	Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).	GSTO1	302663	3200
metabolicEndocrine	endocrine pancreas disorder	IDE	targetBased	Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE)	IDE	324747	1316
metabolicEndocrine	endocrine pancreas disorder	IDE	targetBased	Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE)	IDE	335239	245
hematologic	coagulation protein disease	FGB_inhibitors	targetBased	Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB	369953	498
hematologic	coagulation protein disease	FGB_inhibitors	targetBased	Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB	369953	760
biologicalProcess	prospectiveBiology	ASAP1_inhibitors	targetBased	Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)	ASAP1	362577	680
nervousSystem	AD	ARFGAP1_inhibitors	targetBased	Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1)	ARFGAP1	362539	954
geneticDisorder	cardioacrofacial dysplasia 2	PRKACB	targetBased	Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex	PRKACB	343468	273
cancer	neoplastic disease or syndrome	PRKAR1A	targetBased	Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	343468	285
immune	autoimmune disease	SIAE	targetBased	Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE)	SIAE	369933	2555
metabolicEndocrine	obesity	ABHD4_inhibitors	targetBased	Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).	ABHD4	369953	2005
rareDiseases	cysticFibrosis	cftrTrafficModulators	targetBased	Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	CFTR	296501	2737
cancer	neoplastic disease or syndrome	KEAP1	targetBased	Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	336894	489
antiBacterial	tuberculosis	Mycobacterium tuberculosis	targetBased	Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity	FadD28	355054	777
antiViral	HHV-8	Human herpesvirus 8	targetBased	Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction	LANA1	323564	1946
immune	type II hypersensitivity reaction disease	PLK1	targetBased	Fluorescence polarization assay for PLK1 inhibitors	PLK1	97099	518
cancer	neoplastic disease or syndrome	KLK7	targetBased	Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen	KLK7	368927	3325
antiBacterial	tuberculosis	Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)	targetBased	Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity	RECA	293376	2191
cancer	neoplastic disease or syndrome	RCE1	targetBased	Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of the Ras-converting Enzyme	RCE1	294698	799
biologicalProcess	cellDivision	RanGTP-Importin-beta complex inhibitors	phenotypic	Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex		302387	3282
cancer	neoplastic disease or syndrome	HDAC3	targetBased	Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	318291	483
antiFungal	candidiasis	fluconazole-resistant C.albicans	phenotypic	Fluorescence Cell-Based Primary HTS of C.albicans growth in the presence of Fluconazole and compound	HSP90	302451	1736
cancer	cancerGeneral	rosLevels	phenotypic	Fluorescence Cell-Based Primary HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity		45939	901
otherPhenotypes	age at menarche	KDM4C	targetBased	Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity	KDM4C	326066	228
immune	immunomodulation	CTL granule exocytosis	phenotypic	Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library		363875	2400
biologicalProcess	drugTransport	ABCB6_inhibitors	targetBased	Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6	362098	692
cardioVascular	antithrombotic	F12_modulation	targetBased	Factor XIIa 1536 HTS	F12	217430	649
cardioVascular	antithrombotic	F11_modulation	targetBased	Factor XIa 1536 HTS	F11	218707	302
cancer	cancerGeneral	EZH2_inhibitors	targetBased	EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2	57013	201
antiBacterial	P. aeruginosa	Pseudomonas aeruginosa	targetBased	Epi-absorbance primary biochemical high throughput screening assay to identify inhibitors of IMP-1 metallo-beta-lactamase	BLAIMP-1	290726	1322
nervousSystem	inherited neurodegenerative disorder	TDP2	targetBased	Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2)	TDP2	369953	1241
antiBacterial	tuberculosis	Mycobacterium tuberculosis, non-replicating, drug-tolerant	phenotypic	Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis		324433	1277
cancer	neoplastic disease or syndrome	MDM2	targetBased	E3 Ligase HTS_1536	MDM2	207811	220
nervousSystem	geneticNeurodevelopmentalDisability	DYRK1A_inhibitors	targetBased	Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A	310014	1321
antiViral	HCMV	Human cytomegalovirus	targetBased	Discovery of Small Molecules to Inhibit Human Cytomegalovirus Nuclear Egress	NEC2	183911	278
antiViral	H1N1	Influenza A virus	targetBased	Discovery of Small Molecule Probes for H1N1 Influenza NS1A	NS1	335224	1010
hematologic	normocytic anemia	RACGAP1	targetBased	Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP - Primary and Confirmatory Screens	RACGAP1	342059	2057
respiratory	respiratoryDisorders	CHRM1_allosteric_antagonists	targetBased	Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1	63656	2179
nervousSystem	neurodegeneration	CHRM1_allosteric_activators	targetBased	Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1	63676	1938
cancer	cancerGeneral	Dicer_inhibitors	targetBased	Dicer-mediated maturation of pre-microRNA	DICER1	46715	2829
cancer	neoplastic disease or syndrome	NSD2	targetBased	Development of Small Molecule Probes of the Histone Methyltransferase, NSD2 Measured in Biochemical System Using Plate Reader - 7053-01_Inhibitor_SinglePoint_HTS_Activity_Set2	NSD2	309684	1662
antiViral	Dengue	dengueVirus	phenotypic	DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity		343305	5946
notSpecified	notSpecified	CYP2C19_inhibitors	targetBased	CYP2C19 Assay	CYP2C19	95857	20295
notSpecified	notSpecified	CYP2C9_inhibitors	targetBased	CYP2C9 Assay	CYP2C9	95858	18730
antiBacterial	E. coli	Escherichia coli O157:H7	targetBased	Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin	STX1	295619	37013
cancer	neoplastic disease or syndrome	LYPLA1	targetBased	Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).	LYPLA1	314999	499
nervousSystem	behavioralDisorders	AVPR1A_agonists	targetBased	Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A	324747	813
psychiatricDisorder	schizophrenia	HTR5A	targetBased	Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	335239	279
nervousSystem	neurodegeneration	PPP1CA	targetBased	Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).	PPP1CA	314999	2841
antiViral	EBV	Epstein-Barr virus	targetBased	Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.	P03206	314999	485
antiBacterial	H. pylori	Helicobacter pylori	phenotypic	Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability		326024	893
nervousSystem	neurodegeneration	UHRF1	targetBased	Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide	UHRF1	369953	2779
psychiatricDisorder	schizophrenia	HTR5A	targetBased	Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	335239	2035
antiBacterial	Leuconostoc mesenteroides	Leuconostoc mesenteroides	targetBased	Counter Screen for Glucose-6-Phosphate Dehydrogenase-based Primary Assay	ZWF	195560	236
visualSystem	eye disease	NLRP1	targetBased	Colorimetric Assay for Inhibitors for NALP1	NLRP1	280024	1717
antiBacterial	cholera	Vibrio cholerae BH1578 strain	phenotypic	Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity		349947	553
biologicalProcess	mitochondrialFusion	mitochondrialFusion	phenotypic	Chemical Genetic Screen to Identify Inhibitors of Mitochondrial Fusion - Primary Screen		194153	4011
metabolicEndocrine	body fat percentage	GPR151	targetBased	Cell-based high throughput primary assay to identify activators of GPR151	GPR151	642701	6746
geneticDisorder	chromosomal disorder	PMP22	targetBased	Cell-based coincidence reporter assay to measure PMP22 gene transcription in S16 Pmp22-F2sN cells - Primary screen	PMP22	42576	834
nervousSystem	longTermMemory	_modulators	targetBased	Cell signaling CRE-BLA (Fsk stim)	CREB	69669	1744
biologicalProcess	cytotoxicity	cytotox	phenotypic	cell growth assays at ChEMBL
antiMicrobial	malaria	Plasmodium falciparum	phenotypic	Calibr Malaria Delayed Death Assay SOP		37708	433
antiBacterial	C. difficile	TcdB glycohydrolaseInhibitors	targetBased	C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity	ToxB	349124	837
antiViral	HHV-8	Human herpesvirus 8	targetBased	C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity	ORF73	336515	262
antiArthropodal	hyphantria cunea	hyphantria cunea	targetBased	Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition	LGR2	375648	1337
nervousSystem	PD	D2_PAMs	targetBased	Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	DRD2	357537	806
nervousSystem	psychosis	D2_antagonists	targetBased	Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	DRD2	362274	1056
nervousSystem	PD	D2_agonists	targetBased	Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	DRD2	359518	300
cancer	breastCancer	BrCaAvg	phenotypic	avg of cell line screens at ChEMBL
cancer	cancerGeneral	ARRB1_inhibitors	targetBased	Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling	ARRB1	338373	1061
psychiatricDisorder	mental or behavioural disorder	GRM8	targetBased	Assay for HTS of Gi/Go-linked GPCRs using mGluR8: Primary Screening	GRM8	105151	2166
cancer	neoplastic disease or syndrome	TACC3	targetBased	ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity	TACC3	391179	2589
antiViral	BTV	Bluetongue virus (BTV)	phenotypic	Anti-Viral Drugs Against Arbovirus Infections, a Primary Screen		195407	715
antiMicrobial	malaria	Plasmodium falciparum (isolate 3D7)	targetBased	Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2	811999	307132	972
metabolicEndocrine	thyroid disease	TSHR	targetBased	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	329153	670
nervousSystem	psychosis	D1_inhibitors	targetBased	Antagonist of Human D 1 Dopamine Receptor: qHTS	DRD1	355805	11440
cancer	cancerGeneral	Pyk2	targetBased	Antagonist identification of Pyk2 oligomerization: high-throughput screening cellular assay	PTK2B	98749	818
cancer	cancerGeneral	ULK1	targetBased	AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of Unc-51 Like Autophagy Activating Kinase 1 (ULK1).	ULK1	30185	575
cancer	melanoma	MITF inhibitors	targetBased	AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF	642362	5830
cancer	cancerGeneral	E3 ligase activators	targetBased	AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).	FBW7	641445	853
nervousSystem	Huntington disease	HTT	targetBased	Alphascreen assay for small molecules abrogating mHTT-CaM Interaction	HTT	189882	6790
nervousSystem	PD	D1	targetBased	Allosteric Modulators of D1 Receptors: Primary Screen	DRD1	57705	3413
nervousSystem	PD	D1_activators	targetBased	Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	DRD1	361330	3713
geneticDisorder	developmental defect during embryogenesis	MTOR	pathwayBased	Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	43989	342
nervousSystem	neurodegeneration	FOSB	targetBased	Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity	FOSB	337391	3330
biologicalProcess	apoptosis	procaspase3Activators	targetBased	Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3	CASP3	326024	350
antiBacterial	E. coli	Escherichia coli (strain K12)	targetBased	Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage)	RECD	362577	949
antiBacterial	H. pylori	Helicobacter pylori	targetBased	Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex	AddAB	326024	935
		MSRA	targetBased	Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA)	MSRA	362577	2709
immune	fibrosis	MSRA	targetBased	Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA)	MSRA	362026	1074
biologicalProcess	aging	superoxideGenerationInhibitors	phenotypic	A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide		328830	590
antiBacterial	salmonellosis	Salmonella Typhi	targetBased	A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium	PhoB/PhoR	300458	474
antiBacterial	salmonellosis	Salmonella Typhimurium	targetBased	A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi	PhoB/PhoR	305999	1018
nervousSystem	neurodegeneration	UCHL5	targetBased	A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37	UCHL5	330707	1075
antiViral	Poliovirus type 1	Poliovirus type 1	targetBased	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	P03300	151525	1001
antiBacterial	tuberculosis	Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)	targetBased	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	MENB	102628	440
antiBacterial	anthrax	Bacillus anthracis	targetBased	A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis	CapD	138854	320
antiBacterial	tuberculosis	Mycobacterium tuberculosis (strain CDC 1551 / Oshkosh)	targetBased	A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI	MBTI	104192	927
antiBacterial	S. aureus	Staphylococcus aureus	targetBased	A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus	LtaS	168223	878
antiBacterial	cholera	Vibrio cholerae serotype O1	phenotypic	A screen for compounds that inhibit replication of Vibrio cholerae chromosome II	AAF95916	132441	351
antiViral	VACV	Vaccinia virus (VACV)	targetBased	A screen for compounds that inhibit processive DNA synthesis of vaccinia virus	OPG071	45651	427
antiBacterial	E. coli	Escherichia coli	phenotypic	A screen for compounds that inhibit growth of Escherichia coli		327980	699
antiBacterial	S. aureus	Staphylococcus aureus	phenotypic	A screen for compounds that inhibit cell wall-associated teichoic acid synthesis in Staphylococcus aureus		51739	4434
antiBacterial	S. aureus	Staphylococcus aureus RN4220	phenotypic	A screen for compounds that are lethal to S. aureus RN4220 with the processive glycosyltransferase UgtP deleted		327980	1782
antiBacterial	S. aureus	Staphylococcus aureus RN4220	phenotypic	A screen for compounds that are lethal to S. aureus RN4220		327980	1062
		PARK2	pathwayBased	A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression	PARK2	406283	823
muculoEskeletalConnective	bone disease	GMNN	targetBased	A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.	GMNN	342279	6233
muculoEskeletalConnective	bone disease	GMNN	targetBased	A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.	GMNN	343234	9888
antiBacterial	E. coli	Escherichia coli O157:H7	targetBased	A qHTS for Small Molecule Inhibitors of Shiga Toxin	STX1	292805	26874
antiViral	VEEV	Venezuelan equine encephalitis virus	phenotypic	A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83		347901	453
antiViral	RSV	Respiratory syncytial virus	phenotypic	A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV)		313719	409
antiViral	HIV	HIV type 1	targetBased	384-well Z-Lyte format Hck-Nef inhibitor HTS run at the PMLSC	Hck-Nef	220222	1495
antiBacterial	11_bacterialStrains	antibacterial	phenotypic	11 gram + & - bacterial strains at ChEMBL
cancer	lungCancer	LuCa cell lines	phenotypic	11 cell line screens at ChEMBL
cancer	colonCancer	CoCa cell lines	phenotypic	9 cell line screens at ChEMBL
cancer	breastCancer	BrCa cell lines	phenotypic	8 cell line screens at ChEMBL

OpenTargets DB provides comprehensive insights into the relationships between genes, diseases, and drugs by combining data from various sources, including genomics, transcriptomics, and clinical research. Each gene from PubChem target-based screens will have multiple scored associations to multiple diseases based on qualitative and quantitative information from mentioned data sources so that indications recorded in PubChem can be expanded to a wide range of indications in multiple therapeutic areas.

Check it in the drTarget expanded indications portfolio.

GO TO EXPANDED INDICATIONS PORTFOLIO

Targets association to different therapeutic areas as defined in OpenTargetsDB.

Graph view of the interconnection of target and diseases associations through different disease types.

Partner with DrTarget for AI-Optimized Screening

We welcome collaborations with biotech companies, research institutions, and pharmaceutical partners looking to leverage AI for drug discovery. Get in touch to explore custom screening solutions and accelerate your research.

DrTarget Portfolio 2025: Advancing AI-Powered Drug Discovery

Expanding Virtual Screening Capabilities

DrTarget’s 2025 portfolio integrates over 500 new AI-powered virtual screening programs, leveraging data from 800+ PubChem bioassays. These programs enable the exploration of 2 million molecules across a diverse range of therapeutic areas, accelerating early-stage drug discovery.

Harnessing PubChem Data for Smarter Discovery

By integrating vast datasets from PubChem & ChEMBL, DrTarget refines hit identification strategies, ensuring high-confidence predictions for experimental validation. Our approach facilitates:

🔹 AI-enhanced lead optimization🔹 Chemical property assessment for drug-likeness🔹 Advanced computational workflows for novel targets

802 Pubchem assays support 576 machine learning projects associated to 249 diseases corresponding to 29 therapeutic areas. The assays involve > 400 different phenotypes and 461 genes.

See PubChem assays supporting machine learning programs clicking in the therapeutic area tabs.

Nervous system diseases treeMap with PubChem assays supporting machine learning on them. Click to expand treemaps.

Bacterial diseases treeMap with PubChem assays supporting machine learning on them. Click to expand treemaps.

Immune system diseases treeMap with PubChem assays supporting machine learning on them. Click to expand treemaps.

Viral diseases treeMap with PubChem assays supporting machine learning on them. Click to expand treemaps.

Go to different cancer types and assays supporting virtual screens against them. Click to expand treemaps.

Nervous system diseases treeMap with PubChem assays supporting machine learning on them. Click to expand treemaps.

Bioprocesses treeMap with PubChem assays supporting machine learning on them. Click to expand treemaps.

Cardiovascular diseases treeMap with PubChem assays supporting machine learning on them. Click to expand treemaps.

Psychiatric diseases treeMap with PubChem assays supporting machine learning on them. Click to expand treemaps.

Respiratory diseases treeMap with PubChem assays supporting machine learning on them. Click to expand treemaps.

Protozan infections treeMap with PubChem assays supporting machine learning on them. Click to expand treemaps.

Musculoeskeletal diseases treeMap with PubChem assays supporting machine learning on them. Click to expand treemaps.

Rare diseases treeMap with PubChem assays supporting machine learning on them. Click to expand treemaps.

Genetic disorders treeMap with PubChem assays supporting machine learning on them. Click to expand treemaps.

Other proliferative diseases treeMap with PubChem assays supporting machine learning on them. Click to expand treemaps.

Other non-proliferative diseases treeMap with PubChem assays supporting machine learning on them. Click to expand treemaps.

Partner with DrTarget for AI-Optimized Screening

We welcome collaborations with biotech companies, research institutions, and pharmaceutical partners looking to leverage AI for drug discovery. Get in touch to explore custom screening solutions and accelerate your research.

🔹 AI-enhanced lead optimization
🔹 Chemical property assessment for drug-likeness
🔹 Advanced computational workflows for novel targets